

Stock Code: 3218



UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

2025 General Shareholders' Meeting

Proceedings Manual

May 26, 2025

4F, G Building, No. 3-1, Yuanqu St., Nangang District, Taipei City
(Visual communication assisted shareholders meeting)

Table of Contents

| | |
|------------------------------------------------------------------------------------------------------------|----|
| I. Procedures of Meeting | 1 |
| II. Meeting Agenda..... | 2 |
| 1. Matters to be Reported | 3 |
| 2. Matters for Acknowledgment..... | 8 |
| 3. Matters for Discussion | 9 |
| 4. Extraordinary Motions | 10 |
| III. Appendix | |
| 1. 2024 Business Report..... | 11 |
| 2. Audit Committee Review Report | 17 |
| 3. 2024 Financial Statements and Auditors’ Report | 18 |
| 4. 2024 Consolidated Financial Statements and Auditors’ Report..... | 26 |
| 5. 2024 Statement of the Distribution of Earnings | 34 |
| 6. Comparison Table of Articles of Incorporation Before and After Revision..... | 35 |
| 7. Comparison Table of Procedures for Acquisition or Disposal of Assets Before and After Revision | 37 |
| 8. Comparison Table of Procedures for Lending Funds to Other Parties Before and After Revision..... | 39 |
| 9. Comparison Table of Rules of Procedure for Shareholders Meetings Before and After Revision..... | 41 |
| IV. Annex | |
| 1. Articles of Incorporation (Before Revision)..... | 46 |
| 2. Rules of Procedure for Shareholders Meetings (Before Revision)..... | 53 |
| 3. Shareholding Status of All Directors | 59 |

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.
Procedure of the 2025 General Shareholders' Meeting

1. Call Meeting to Order
2. Chairperson's Address
3. Matters to be Reported
4. Matters for Acknowledgment
5. Matters for Discussion
6. Extraordinary Motions
7. Adjournment

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Agenda of the 2025 General Shareholders' Meeting

The date and location of the shareholders' meeting:

Visual communication assisted shareholders meeting (meeting convened physically, supplemented by video conference)

Time: 9:00 a.m. on May 26, 2025 (Monday)

Physical shareholders' meeting venue:

4F, G Building, No. 3-1, Yuanqu St., Nangang District, Taipei City

Video conference platform:

Taiwan Depository & Clearing Corporation "Stock Services Platform" – eMeeting platform (URL: <https://stockservices.tdcc.com.tw>)

1. Call Meeting to Order (Report the number of shares attended)
2. Chairperson's Address
3. Matters to be Reported
 - (1) 2024 Business Report
 - (2) 2024 Final Accounts Report reviewed by the Audit Committee
 - (3) Report on the distribution status of 2024 employee compensation and director remuneration
 - (4) Report on the distribution status of 2024 cash dividends
 - (5) Report on the investment status in Mainland China
 - (6) Report on the status of undertaking the endorsement and guarantee
 - (7) Report on the Company's 2024 director remuneration
4. Matters for Acknowledgment
 - (1) Acknowledgment of 2024 business report and financial statements
 - (2) Acknowledgment of 2024 Statement of the Distribution of Earnings
5. Matters for Discussion
 - (1) Discussion to revise the Company's Articles of Incorporation
 - (2) Discussion to revise the Company's Procedures for Acquisition or Disposal of Assets
 - (3) Discussion to revise the Company's Procedures for Lending Funds to Other Parties
 - (4) Discussion to revise the Company's Rules of Procedure for Shareholders Meetings
6. Extraordinary Motions
7. Adjournment

【Matters to be Reported】

1. The 2024 business report is submitted for your review.

Description:

Please refer to Appendix 1 (pages 11-16) to this Handbook for the Company's 2024 business report.

2. The 2024 final accounts report reviewed by the Audit Committee is submitted for your review.

Description:

Please refer to Appendix 2 (page 17) to this Handbook for the final accounts report reviewed by the Audit Committee of the Company.

3. The report on the distribution status of 2024 employee compensation and director remuneration is submitted for your review.

Description:

- (1) The distribution of 2024 employee compensation and director remuneration of the Company was handled in accordance with Article 30 of the Company's Articles of Incorporation.
- (2) The distribution amount of employee compensation was NT\$41,314,974, and the distribution amount of director remuneration was NT\$17,111,487, accounting for 3.00% and 1.24% respectively of the profit before tax and before distribution deduction of employee and director remuneration, both of which were paid in cash and were not different from the estimated amounts recorded in the accounts.

4. The report on the distribution status of 2024 cash dividends is submitted for your review.

Description:

- (1) This case is processed in accordance with Article 30-1 of the Company's Articles of Incorporation.
- (2) As approved by the Board of Directors on March 6, 2025, the Company shall distribute cash dividends to shareholders in the amount of NT\$635,436,743 out of the distributable earnings for the year 2024, with each share being distributed with a dividend of NT\$7.5, distributed on April 21, 2025.

5. The report on the investment status in Mainland China is submitted for your review.

Description:

The Company applied to the Investment Commission of the Ministry of Economic Affairs in October 2002, January 2011, June 2014, February 2018, December 2018, and August 2020 respectively for an indirect investment in the amount of US\$26 million in the investee company in Mainland China, Universal Vision Biotechnology (Shanghai) Co., Ltd., which was approved by the said Commission. As of March 31, 2025, the Company had accumulatively made the outward remittances for the investment funds in the amount of US\$23 million.

The Company recognized the investment loss of its indirect reinvestment in Universal Vision Biotechnology (Shanghai) Co., Ltd. in the amount of NT\$67,520,000 in 2024. As of December 31, 2024, the carrying amount was NT\$419,844,000.

6. The report on the status of undertaking the endorsement and guarantee is submitted for your review.

Description:

As of March 31, 2025, the status of the endorsement and guarantees the Company provided to the subsidiaries in accordance with the “Procedures for Endorsement and Guarantee” is set out in the table below.

| No. | Guarantee | Relationship to this Company | Financing institution | Guaranteed amount | | Actual amount borrowed | |
|-----|-------------------------------------|-------------------------------------|-----------------------|-------------------|-------------------|------------------------|-------------------|
| | | | | Currency | Amount (thousand) | Currency | Amount (thousand) |
| 1 | Kunshan Universal Trading Co., Ltd. | 70% owned subsidiary of the company | Bank SinoPac | USD | 3,000 | USD | - |

Note: The above amount does not exceed the specified limit.

7. The report on the Company's 2024 director remuneration is submitted for your review.

Description:

(1) The relationships between the distribution policy, standard and combination, and procedures for the remuneration of the Company with business performance and future risks:

I. Article 25-1 of the Company's Articles of Incorporation authorizes the Board of Directors to determine director remuneration according to the level of each director's participation in the operation and the value of their contribution, and take into account the domestic standards of the same trade. Additionally, in accordance with Article 30 of the Articles of Incorporation, if there are any remaining profits in the prevailing year, no more than 3% of the prevailing year's profits may be distributed as director remuneration.

II. Director remuneration is regularly evaluated in accordance with the Rules for Performance Evaluation of Board of Directors. The major evaluation items are comprehensively considered for director remuneration as follows:

i. Business performance: Comprehensively references factors from this year including the 8% growth of the operating revenue and the 3% increase of the pre-tax net profits.

ii. Annual rating: References the Company being ranked among the top 5% of TPEX-listed companies in the Corporate Governance Evaluation, and the results of Board of Directors and functional committee annual performance evaluations, all of which were remarkably outstanding.

iii. Peer level: References the average level of director remuneration provided by the peer TPEX listed companies.

The above results indicate the sound overall operation and excellent performance of the Company's Board of Directors.

III. The director remuneration for this year accounts for 2.30% of net profit after tax. The actual amount of director remuneration paid this year was reviewed by the Compensation Committee and then resolved upon by the Board of Directors.

IV. The distribution policy for the director remuneration of the Company is positively related to the operating performance and future risks. The rationality of director remuneration is regularly evaluated by both the Compensation Committee and the Board of Directors. In addition to considering individual directors' individual responsibilities and contributions, the Company's overall operating performance, industrial development trends and future risks are also considered as the criteria for determining the payment; the remuneration system is also reviewed in a timely manner in accordance with relevant laws and regulations to improve the efficiency of the board's operations.

(2) The details of the individual director remuneration are shown on the following page:

Unit: Thousand NT\$

| Position | Name | Remuneration to Directors | | | | | | | | Remuneration to the capacity as employees | | | | | | | | The sum of A, B, C, E, F and G and proportion to net profit after tax | | Remuneration received from an invested company other than the company's subsidiary or parent company | | |
|----------------------|----------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------|-------------|-----------------------------------------------------|----------------------------------------|-----------------------------------------------------|---------------------------------|-----------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|---------------------------------------------|-----------------------------------------------------|-------------|-----------------------------------------------------|-------------------------------|---|-----------------------------------------------------------------------|---|------------------------------------------------------------------------------------------------------|----------------|-----------------------------------------------------|
| | | Remuneration (A) | | Pension (B) | | Remuneration to directors (C) (Note 1) | | Business execution expenses (D) | | The sum of A, B, C and D and proportion to net profit after tax | | Salaries, bonus and special disbursement(E) | | Pension (F) | | Remuneration to employees (G) | | | | | | |
| | | The Company | All companies mentioned in the financial statements | The Company | All companies mentioned in the financial statements | The Company | All companies mentioned in the financial statements | The Company | All companies mentioned in the financial statements | The Company | All companies mentioned in the financial statements | The Company | All companies mentioned in the financial statements | The Company | All companies mentioned in the financial statements | The Company | | All companies mentioned in the financial statements | | | The Company | All companies mentioned in the financial statements |
| Chairperson | Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang | 2,184 | 2,184 | - | - | 2,390 | 2,390 | 60 | 60 | 4,634 0.44% | 4,634 0.44% | - | - | - | - | - | - | - | - | 4,634 0.44% | 4,634 0.44% | None |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung | - | - | - | - | 2,390 | 2,390 | 60 | 60 | 2,450 0.23% | 2,450 0.23% | 962 | 962 | 58 | 58 | - | - | - | - | 3,470 0.33% | 3,470 0.33% | None |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der | - | - | - | - | 2,390 | 2,390 | 60 | 60 | 2,450 0.23% | 2,450 0.23% | - | - | - | - | - | - | - | - | 2,450 0.23% | 2,450 0.23% | None |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei | - | - | - | - | 2,390 | 2,390 | 60 | 60 | 2,450 0.23% | 2,450 0.23% | - | - | - | - | - | - | - | - | 2,450 0.23% | 2,450 0.23% | None |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen (Note 2) | - | - | - | - | 1,593 | 1,593 | 40 | 40 | 1,633 0.15% | 1,633 0.15% | - | - | - | - | - | - | - | - | 1,633 0.15% | 1,633 0.15% | None |
| Independent Director | Xiao Min-Zhi | 900 | 900 | - | - | 1,490 | 1,490 | 60 | 60 | 2,450 0.23% | 2,450 0.23% | - | - | - | - | - | - | - | - | 2,450 0.23% | 2,450 0.23% | None |
| Independent Director | Liu Vincent | 900 | 900 | - | - | 1,490 | 1,490 | 60 | 60 | 2,450 0.23% | 2,450 0.23% | - | - | - | - | - | - | - | - | 2,450 0.23% | 2,450 0.23% | None |
| Independent Director | Yang Yun-Hua | 900 | 900 | - | - | 1,490 | 1,490 | 60 | 60 | 2,450 0.23% | 2,450 0.23% | - | - | - | - | - | - | - | - | 2,450 0.23% | 2,450 0.23% | None |
| Independent Director | Chen Wei-Ru (Note 2) | 600 | 600 | - | - | 993 | 993 | 40 | 40 | 1,633 0.15% | 1,633 0.15% | - | - | - | - | - | - | - | - | 1,633 0.15% | 1,633 0.15% | None |
| Independent Director | Chen Yan-Jun (Note 3) | 300 | 300 | - | - | 496 | 496 | 20 | 20 | 816 0.08% | 816 0.08% | - | - | - | - | - | - | - | - | 816 0.08% | 816 0.08% | None |

Note 1: The 2024 director remuneration was an estimate.

Note 2: Newly appointed on June 19, 2024.

Note 3: Dismissed on June 19, 2024.

【Matters for Acknowledgment】

Agenda 1 (proposed by the Board of Directors)

Proposal: The 2024 business report and financial statements are submitted for acknowledgment.

Description:

1. The audit of the Company's 2024 financial statements and consolidated financial statements has been completed by the certified public accountant Kuo Nai-Hua and the certified public accountant Chen Chung-Cheng from Deloitte & Touche, and a written audit report has been issued.
2. For the 2024 business report, certified public accountant's audit report, and the aforementioned financial statements, please refer to Appendix 1 (pages 11-16) and Appendixes 3-4 (pages 18-33) to this Handbook.
3. Please acknowledge the proposal.

Resolution:

Agenda 2 (proposed by the Board of Directors)

Proposal: The 2024 Statement of the Distribution of Earnings is submitted for acknowledgment.

Description:

1. The review of the Company's 2024 Statement of the Distribution of Earnings had been completed by the Audit Committee and submitted to the Board of Directors for approval.
2. For the 2024 Statement of the Distribution of Earnings, please refer to Appendix 5 (page 34) to this Handbook.
3. Please acknowledge the proposal.

Resolution:

【Matters for Discussion】

Agenda 1 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Articles of Incorporation is submitted for deliberation.

Description:

1. In response to the amendments to the laws and regulations, it is proposed to revise some provisions of the Company's Articles of Incorporation. For the comparison table of the provisions before and after the revision, please refer to Appendix 6 (pages 35-36) to this Handbook.
2. Please deliberate on this matter.

Resolution:

Agenda 2 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Procedures for Acquisition or Disposal of Assets is submitted for deliberation.

Description:

1. In response to the Company's operational needs, it is proposed to revise some provisions of the Company's Procedures for Acquisition or Disposal of Assets. For the comparison table of the provisions before and after the revision, please refer to Appendix 7 (pages 37-38) to this Handbook.
2. Please deliberate on this matter.

Resolution:

Agenda 3 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Procedures for Lending Funds to Other Parties is submitted for deliberation.

Description:

1. In response to the Company's practical operational needs, it is proposed to revise some provisions of the Company's Procedures for Lending Funds to Other Parties. For the comparison table of the provisions before and after the revision, please refer to Appendix 8 (pages 39-40) to this Handbook.
2. Please deliberate on this matter.

Resolution:

Agenda 4 (proposed by the Board of Directors)

Proposal: The proposal to revise the Company's Rules of Procedure for Shareholders Meetings is submitted for deliberation.

Description:

1. In response to the Company's practical operational needs, it is proposed to revise some provisions of the Company's Rules of Procedure for Shareholders Meetings. For the comparison table of the provisions before and after the revision, please refer to Appendix 9 (pages 41-45) to this Handbook.
2. Please deliberate on this matter.

Resolution:

【Extraordinary Motions】

【Adjournment】

Appendix 1

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 2024 Business Report

1. Operating Status in 2024

(1) Operating results:

The Group's consolidated operating revenue in 2024 was NT\$4,228,302 thousand, an increase of 3.58% over the previous year; consolidated net profit attributable to the Company's owners of the parent was NT\$1,064,721 thousand, an increase of NT\$19,627 thousand or 1.88% over the previous year.

The independent operating revenue of the parent company in Taiwan was NT\$3,513,460 thousand in 2024, an increase of 8.42% over the previous year, and the parent company's operating revenue accounted for 83.09% of the Group's consolidated operating revenue. In Taiwan (including Penghu), there were 31 self-owned eyewear stores, contributing sales revenue of NT\$840,819 thousand, making up 23.93% of the total operating revenue and representing a year-on-year increase of 14.70%. With a total of 28 partner clinics, the income generated from brand licensing, technical services, consulting, and rental to the clinics was NT\$2,202,494 thousand, accounting for 62.69% of the total operating revenue and representing a year-on-year increase of 6.42%. The income from medical supplies was NT\$470,147 thousand, accounting for 13.38% of the total operating revenue and representing a year-on-year increase of 7.36%.

(2) Budget implementation status:

The Company's internal budget for the year 2024 had been approved by the Board of Directors, but the financial forecast has not been disclosed to the public. The overall operating condition was good.

(3) Profitability analysis:

Unit: Thousand NT\$

| Item \ Year | | 2024 | 2023 |
|-----------------------------------|--------------------------------------------------------------|-----------|-----------|
| Financial revenue and expenditure | Net consolidated operating revenue | 4,228,302 | 4,082,256 |
| | Consolidated gross profit | 2,533,286 | 2,448,370 |
| | Consolidated net profit attributable to owners of the parent | 1,064,721 | 1,045,094 |
| Profitability | Consolidated return on assets (%) | 19.59 | 22.35 |
| | Consolidated return on shareholders' equity (%) | 29.59 | 34.48 |
| | Consolidated gross margin (%) | 24.84 | 26.06 |
| | Consolidated earnings per share (NT\$) | 12.57 | 12.34 |

(4) Research and development status:

In recent years, the Company has continued to introduce advanced ophthalmic technologies and equipment, including femtosecond laser assisted cataract surgery and SMILE Pro, the next-generation of SMILE Laser Vision Correction. In 2024, the Company further introduced SMILE Pro 2.0, featuring an enhanced AI tracking function, along with a new type of intraocular lens designed to minimize glare. In addition, the Company has supported its partner clinics by providing training and implementation programs related to these new technologies, which have been highly praised by the medical teams of the partner clinics. Such efforts have significantly optimized surgical efficiency and service quality, offering partner clinics more advanced medical options and enhancing the overall brand reputation through positive word-of-mouth recognition.

Furthermore, adhering to the business philosophy of providing high-quality products to the public, the Company established a cross-disciplinary team integrating biotechnology and food science to jointly develop “Universal Gold Lutein”, an eye nutrition supplement suitable for the entire family. The raw materials and manufacturing processes are subject to strict quality control, with formulations specifically tailored to meet the nutritional needs of seniors, adults, and children. In response to the demands of modern digital lifestyles, the Company launched a new “SOS Enhanced” formula, offering comprehensive solutions for maintaining visual clarity and moisture. Since its launch, “Universal Gold Lutein” has received numerous prestigious awards, including the “SNQ Award”, “National Biotechnology and Medical Care Quality Award”, “National Brand Yushan Award”, “Taiwan Excellent Manufacturer Award”, “National Biotechnology Award”, “Monde Selection Gold Quality Award”, and “iTQi Superior Taste Award”. These accolades highlight the Company's unwavering commitment to quality and dedication to safeguarding public health.

2. Summary of Business Plan for 2025

(1) Management Policy and Operation Objectives

A. Ophthalmology market

(a) Laser vision correction market

The laser vision correction market has experienced rapid growth in recent years, with increasing acceptance among the general public. At the end of 2022, the Company introduced SMILE Pro, the next-generation laser vision correction surgery, which features a minimally invasive procedure that reduces dry-eye symptoms while offering enhanced comfort, speed, and safety. This technology has helped partner clinics provide their customers with comprehensive and high-quality vision correction solutions. In 2025, the Company plans to roll out a full range of SMILE, SMILE Pro, and SMILE Pro 2.0 services as part of its market differentiation strategy. In addition to existing refractive laser technologies, the Company has also introduced and developed PresbyLASIK and myopia laser technology equipment for its partner clinics to address the increasing demand from the presbyopic

population. At the same time, the Company is preparing to introduce new implantable contact lens (ICL) technology, offering an optimal solution for patients with high myopia who are unsuitable candidates for corneal laser surgery. Following the introduction of this technology, partner clinics will be able to offer a more comprehensive range of vision correction services.

(b) Cataract market

The Company has continued to support its partner clinics in promoting advanced technologies and applications for femtosecond laser-assisted cataract surgery combined with premium intraocular lens (IOL) selections. This approach offers the advantages of precision medicine and superior post-operative visual outcomes, assisting partner clinics in continuously increasing the adoption rate of the femtosecond laser-assisted cataract procedure. In addition, the Company has introduced a new type of intraocular lens featuring reduced glare and extended depth of focus, further enhancing patient satisfaction with cataract surgery.

(c) Dry-eye treatment market

Demand in the dry eye treatment market is substantial, as many contact lens users, middle-aged individuals, and seniors require ongoing care. Moreover, continuous dry eye management is often necessary following laser vision correction and cataract surgeries. Since 2022, the Company has gradually introduced the dry eye treatment program and equipment into its partner clinics, and patient acceptance has steadily increased over the past two years. It is anticipated that, as patient satisfaction continues to spread through word of mouth, the service volume will grow progressively in the coming years.

B. Optometry market

(a) Innovative technology and precise services: The e-Universal brand leading the Optometry Sector

Leveraging innovative technology, the Company launched “i-Precision Intelligent Prescription”, which integrates 21 examination steps and 21 myopia management measures. The Company is the first to deploy multi-focal stress relief experience equipment from Japan's Hoya and France's Essilor across all our stores, in combination with Zeiss iCM positioning systems, fully automated optometry devices, AI technology, and big data analytics. Together, these solutions provide consumers with a fully personalized, precise, and comfortable eyewear fitting experience. Adhering to the core philosophy of “Medical Optometry, Scientific Eyewear Prescription,” the Company delivers bespoke eyewear solutions for each customer. Our products blend professional expertise, fashion sensibility, and technological innovation, setting us apart from traditional optical retailers and fast-fashion eyewear prescription models. Looking ahead, the Company will continue to strengthen its offerings in myopia control products, senior wellness service packages, lutein eye health supplements and personalized product services, aiming to drive steady growth in both revenue and profitability.

(b) Big Vision Project: Comprehensive eye health management

By integrating the technological strengths and equipment of partner clinics with the Company's self-operated optical stores, the Company actively promotes the importance of myopia control and axial length tracking among school-age children. Through technological innovation and AI applications, the Company continues to introduce advanced optometry equipment and regularly updates a diverse range of myopia control products to enhance customer engagement among students and their parents. Centered around the philosophy of "Lifelong Eye Health Solutions for the Entire Family," the Company has integrated optometry services, myopia prevention and control, and related solutions under the e-Universal brand, establishing itself as the first choice for consumers. This strategy not only strengthens the brand's market value but also delivers comprehensive and reliable eye health solutions to an expanding consumer base.

(2) Important production and marketing strategies

A. Marketing strategy

The Company actively establishes long-term strategic partnerships with major optical and biotechnology corporations, both domestically and internationally, to integrate resource advantages and jointly drive innovation and application in optical products and technologies. Concurrently, the Company continues to invite its partner clinics to participate in public welfare initiatives, integrating professional services with corporate social responsibility. Through these efforts, the Company promotes public awareness of vision health and hygiene, thereby naturally cultivating good habits for healthy eye care among the public.

B. Brand strategy

Centering on the "e-Universal" brand, the Company integrates Taiwan's leading ophthalmic medical and optometric services to provide a comprehensive one-stop solution through its physical retail channels. To further enhance the customer experience, the Company has launched an exclusive e-commerce platform for prescription eyewear and eye care products, achieving seamless integration between online and offline services. This not only serves a broad online customer base but also drives traffic to physical stores. To achieve long-term development objectives, the Company continues to optimize its operational structure and enhance the per-store productivity of its existing locations. Additionally, by leveraging the channel resources of partner clinics and implementing cross-marketing strategies, the Company is comprehensively strengthening its brand impact. Through continuous innovation and professional excellence, the Company is committed to leading the market and achieving its goal of becoming the leading brand in Taiwan's vision optics industry.

(3) Impact of external competitive environment, regulatory environment, and overall business environment

While pursuing corporate growth and achieving operational goals, the Company incorporates ESG (environmental, social, governance) corporate sustainability into our corporate strategies and operations. Through the gradual implementation of ESG initiatives, the Company is committed to sustainable management practices aimed at enhancing service quality and creating long-term corporate value.

In the 10th Corporate Governance Evaluation in 2024, the Company was ranked among the “Top 5% of TPEX-listed Companies” for a second straight year; receiving the highest honor as a “Top 10% of Non-financial/electronic TWSE/TPEX-listed Companies with a Market Value of NT\$10 Billion or Above” for the first time; and performed outstandingly in the four aspects of protecting shareholder rights and interests, strengthening board structure and operations, improving information transparency, and promoting sustainable development. In 2023, the Company was included in Morgan Stanley Capital International (MSCI) ESG A Ratings for the first time, and was subsequently upgraded to AA in 2024. In terms of overall sustainability performance, the Company participated in the 17th Taiwan Corporate Sustainability Awards (TCSA) competition for the first time, and achieved excellent results: a Bronze Award in Sustainability Report-Service Industry Category 1, and an Excellence Award in the Comprehensive Performance-Taiwan Sustainable Enterprise category. In addition, the Company was recognized as a “2024 Outstanding Business Operator” by the Ministry of Finance and received the “TPEX-Listed Medium-Size Partner Award” by the Taipei Exchange. These affirmed the Company’s ongoing contributions to the market through ethical corporate governance and outstanding operational performance.

The Company remains vigilant to changes in the competitive environment, the regulatory environment, and the macroeconomy in order to mitigate potential impact on its operations. In 2024, the Company continued to optimize cyber security by conducting advocacy and training courses on “Information Security”, “Personal Data Protection Act” and “Trade Secrets Act”; put in place information security supervisors and information security personnel; and obtained an iPAS “Information Security Engineer” competency certification and the ISO/IEC 27001:2022 Information Security Management System (ISMS) Lead Auditor training certification. Although the Company’s operations are characterized by low carbon emissions, it actively responds to climate change initiatives by establishing environmental management systems and goals in line with government policies. The Company collaborates closely with supply chain partners to fulfill its commitment to environmental sustainability. Furthermore, the Company has actively promoted “Green Procurement”, prioritizing products with green certifications, and has continuously invested in energy-saving equipment, resulting in a steady year-over-year decline in both total electricity consumption and energy intensity.

The Company fully recognizes its responsibilities and mission to society. Through active participation in public welfare initiatives, investments in the care of disadvantaged groups, emphasis on talent development and community building, and support for domestic cultural advancement, the Company aims to leverage its corporate influence to drive positive social change. In 2024, the Company continued its core initiatives, including vision health awareness activities, charitable eyewear donations, and educational programs promoting eye health. The Company also fully sponsored employee participation in a 1,000-person blood donation drive and the “Love the Earth” charity run held at Neihu Technology Park, demonstrating tangible engagement with the local community. Moreover, the Company actively supports the development of Taiwan’s cultural and creative industries by sponsoring and investing in the creation, production, broadcasting, and performance of works by domestic performing arts groups, cultural organizations, and individual artists across film, television, music, and theater. These efforts align with government policies and contribute to the overall advancement of Taiwan’s cultural and creative sectors.

(4) Future Development Strategy

Universal Vision Biotechnology Co., Ltd. (“UVB”) upholds the corporate philosophy inspired by the “Great Learning”—to manifest one’s bright virtue, to love the people, and to pursue the highest good. Staying aligned with the times, UVB remains committed to continuously introducing cutting-edge medical technologies and advanced technical equipment. We are dedicated to assisting partner clinics in enhancing high-quality medical services and achieving greater customer satisfaction, while integrating our self-operated eyewear stores to deliver fully customized services and products. Striving for excellence, our mission is to pursue the perfect clarity and comfort of vision for every pair of eyes, and to create moments of customer delight and lasting value.

Going forward, UVB will continue to expand distribution channels and develop service platforms, aiming to enable people to “See Clear, See Comfort, See the Future!” Guided by this motto, we will carry on the mission to capture emerging trends in the biotechnology and vision care industries, striving to become a source of pride for Taiwan in the global vision biotechnology industry. We look forward to working together with all stakeholders and wish everyone good health and a prosperous future.

Chairperson: Ou Shu-Fang

General Manager: Lu Kenneth

Accounting Manager: Sun Yu-Chiao

Appendix 2

Audit Committee Review Report

The 2024 business report, financial statements (including parent company only financial statements and consolidated financial statements), the earnings distribution proposal, etc., among which the audit of the financial statements have been completed by the certified public accountants Kuo Nai-Hua and Chen Chung-Cheng from Deloitte & Touche Accounting Firm, who also issued the audit report. The review of the aforementioned business report, financial statements and earnings distribution statement have been completed by the Audit Committee, which believes that there is no inconsistency. This report is hereby made in accordance with the provisions of Article 14-4 of the Securities and Exchange Act as well as Article 219 of the Company Act, and is submitted for your review.

Submitted to

2025 General Shareholders' Meeting of Universal Vision Biotechnology Co., Ltd.

Convener of Audit Committee: Xiao Min-Zhi

March 6, 2025

Appendix 3

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Universal Vision Biotechnology Co., Ltd.

Opinion

We have audited the accompanying parent company only financial statements of Universal Vision Biotechnology Co., Ltd. (the "Company"), which comprise the parent company only balance sheets as of December 31, 2024 and 2023, and the parent company only statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the parent company only financial statements, including material accounting policy information (collectively referred to as the "parent company only financial statements").

In our opinion, the accompanying parent company only financial statements present fairly, in all material respects, the parent company only financial position of the Company as of December 31, 2024 and 2023, and its parent company only financial performance and its parent company only cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements section of our report. We are independent of the Company in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the parent company only financial statements for the year ended December 31, 2024. These matters were addressed in the context of our audit of the parent company only financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter of for the Company's financial statements for the year ended December 31, 2024 is described stated as follows:

Ophthalmology Business Division - Accuracy of Technical Service Revenue

The Company's ophthalmology business division 2024 operating revenue - technical service revenue is the main revenue and is growing year by year, which has a significant impact on independent financial statements; thus, we listed the accuracy of ophthalmology business division -

technical service revenue as a key audit matter. For additional information on the accounting policy of revenue recognition, refer to Note 4.m. to the financial statements.

We have performed principal audit procedures for confirming the accuracy of the ophthalmology business division - technical service revenue as below:

1. We obtained an understanding of the design and tested the implementation effectiveness of internal control of the ophthalmology business division - technical service revenue.
2. We obtained the subsidiary ledger of the ophthalmology business division - technical service revenue and examined the contents, checked the contracts, relevant supporting documents and the collection of receivables to confirm the authenticity of the recognized technical service revenue.

Responsibilities of Management and Those Charged with Governance for the Parent Company Only Financial Statements

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Company's financial reporting process.

Auditors' Responsibilities for the Audit of the Parent Company Only Financial Statements

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision, and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements for the year ended December 31, 2024 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Nai-Hua Kuo and Chung-Cheng Chen.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 6, 2025

Notice to Readers

The accompanying parent company only financial statements are intended only to present the financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such parent company only financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying parent company only financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and parent company only financial statements shall prevail.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY BALANCE SHEETS DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

| ASSETS | 2024 | | 2023 | |
|-----------------------------------------------------------------------------------------------------|---------------------|------------|---------------------|------------|
| | Amount | % | Amount | % |
| CURRENT ASSETS | | | | |
| Cash and cash equivalents (Notes 4 and 6) | \$ 93,414 | 2 | \$ 603,315 | 13 |
| Financial assets at fair value through profit or loss - current (Notes 4 and 7) | 1,295,373 | 24 | - | - |
| Financial assets at amortized cost - current (Notes 4, 9 and 10) | 24,000 | - | 578,363 | 12 |
| Trade receivables (Notes 4, 11 and 23) | 506,811 | 9 | 514,450 | 11 |
| Trade receivables from related parties (Notes 4, 11 and 30) | 7,189 | - | 5,629 | - |
| Other receivables (Note 30) | 9,255 | - | 1,644 | - |
| Inventories (Notes 4 and 12) | 255,774 | 5 | 253,911 | 5 |
| Other current assets | 35,107 | 1 | 31,876 | 1 |
| Total current assets | 2,226,923 | 41 | 1,989,188 | 42 |
| NON-CURRENT ASSETS | | | | |
| Financial assets at fair value through other comprehensive income - non-current (Notes 4, 8 and 10) | 111,073 | 2 | - | - |
| Investments accounted for using the equity method (Notes 4 and 13) | 527,848 | 10 | 574,932 | 12 |
| Property, plant and equipment (Notes 4, 14 and 31) | 1,578,576 | 29 | 1,362,436 | 29 |
| Right-of-use assets (Notes 4 and 15) | 858,064 | 16 | 644,402 | 14 |
| Intangible assets (Notes 4 and 16) | 4,263 | - | 3,401 | - |
| Deferred tax assets (Notes 4 and 25) | 54,990 | 1 | 43,803 | 1 |
| Prepayments for equipment | - | - | 82,386 | 2 |
| Refundable deposits | 33,085 | 1 | 28,543 | - |
| Total non-current assets | 3,167,899 | 59 | 2,739,903 | 58 |
| TOTAL | \$ 5,394,822 | 100 | \$ 4,729,091 | 100 |
| LIABILITIES AND EQUITY | | | | |
| CURRENT LIABILITIES | | | | |
| Short-term borrowings (Notes 17 and 31) | \$ 50,000 | 1 | \$ - | - |
| Trade payables (Note 18) | 225,754 | 4 | 269,235 | 6 |
| Payables for equipment (Note 20) | 90,614 | 2 | 87,279 | 2 |
| Other payables (Note 19) | 228,258 | 4 | 215,509 | 4 |
| Current tax liabilities (Notes 4 and 25) | 143,900 | 3 | 153,747 | 3 |
| Lease liabilities - current (Notes 4 and 15) | 143,982 | 3 | 123,212 | 3 |
| Other current liabilities (Note 23) | 21,052 | - | 20,150 | - |
| Total current liabilities | 903,560 | 17 | 869,132 | 18 |
| NON-CURRENT LIABILITIES | | | | |
| Deferred tax liabilities (Notes 4 and 25) | 47,053 | 1 | 38,060 | 1 |
| Lease liabilities - non-current (Notes 4 and 15) | 750,713 | 14 | 551,148 | 12 |
| Long-term accounts payable (Note 20) | 70,908 | 1 | 92,574 | 2 |
| Guarantee deposits | 575 | - | 535 | - |
| Total non-current liabilities | 869,249 | 16 | 682,317 | 15 |
| Total liabilities | 1,772,809 | 33 | 1,551,449 | 33 |
| EQUITY (Note 22) | | | | |
| Share capital | | | | |
| Ordinary shares | 847,249 | 16 | 847,249 | 18 |
| Capital surplus | 381,924 | 7 | 381,924 | 8 |
| Retained earnings | | | | |
| Legal reserve | 378,623 | 7 | 278,614 | 6 |
| Special reserve | 11,384 | - | 5,042 | - |
| Unappropriated earnings | 1,998,328 | 37 | 1,676,197 | 35 |
| Total retained earnings | 2,388,335 | 44 | 1,959,853 | 41 |
| Other equity | 4,505 | - | (11,384) | - |
| Total equity | 3,622,013 | 67 | 3,177,642 | 67 |
| TOTAL | \$ 5,394,822 | 100 | \$ 4,729,091 | 100 |

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

| | 2024 | | 2023 | |
|---------------------------------------------------------------------------------------------------------------|---------------------|-------------|---------------------|-------------|
| | Amount | % | Amount | % |
| OPERATING REVENUE (Notes 4, 23 and 30) | \$ 3,513,460 | 100 | \$ 3,240,692 | 100 |
| OPERATING COSTS (Notes 12 and 24) | <u>(1,361,200)</u> | <u>(39)</u> | <u>(1,270,538)</u> | <u>(39)</u> |
| GROSS PROFIT | <u>2,152,260</u> | <u>61</u> | <u>1,970,154</u> | <u>61</u> |
| OPERATING EXPENSES (Notes 21 and 24) | | | | |
| Selling and marketing expenses | (433,851) | (12) | (375,713) | (12) |
| General and administrative expenses | (302,812) | (9) | (316,842) | (10) |
| Expected credit loss | <u>-</u> | <u>-</u> | <u>(4,227)</u> | <u>-</u> |
| Total operating expenses | <u>(736,663)</u> | <u>(21)</u> | <u>(696,782)</u> | <u>(22)</u> |
| PROFIT FROM OPERATIONS | <u>1,415,597</u> | <u>40</u> | <u>1,273,372</u> | <u>39</u> |
| NON-OPERATING INCOME AND EXPENSES | | | | |
| Interest income (Note 24) | 36,248 | 1 | 14,759 | 1 |
| Other income (Notes 24 and 30) | 7,263 | - | 6,498 | - |
| Other gains and losses (Note 24) | (97,333) | (3) | (1,148) | - |
| Finance costs (Note 24) | (15,697) | - | (10,030) | - |
| Share of loss or profit of subsidiaries, associates and joint ventures (Note 4) | <u>(27,339)</u> | <u>(1)</u> | <u>2,305</u> | <u>-</u> |
| Total non-operating income and expenses | <u>(96,858)</u> | <u>(3)</u> | <u>12,384</u> | <u>1</u> |
| PROFIT BEFORE INCOME TAX | 1,318,739 | 37 | 1,285,756 | 40 |
| INCOME TAX EXPENSE (Notes 4 and 25) | <u>(254,018)</u> | <u>(7)</u> | <u>(240,662)</u> | <u>(8)</u> |
| NET PROFIT FOR THE YEAR | <u>1,064,721</u> | <u>30</u> | <u>1,045,094</u> | <u>32</u> |
| OTHER COMPREHENSIVE INCOME (LOSS) | | | | |
| Items that may be reclassified subsequently to profit or loss: | | | | |
| Exchange differences on translation of the financial statements of foreign operations (Note 22) | 23,420 | 1 | (7,936) | - |
| Unrealized loss on investments in debt instruments at fair value through other comprehensive income (Note 22) | (3,559) | - | - | - |
| Income tax relating to items that may be reclassified subsequently to loss or profit (Notes 4 and 25) | <u>(3,972)</u> | <u>-</u> | <u>1,587</u> | <u>-</u> |
| Other comprehensive income (loss) for the year, net of income tax | <u>15,889</u> | <u>1</u> | <u>(6,349)</u> | <u>-</u> |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR | <u>\$ 1,080,610</u> | <u>31</u> | <u>\$ 1,038,745</u> | <u>32</u> |
| EARNINGS PER SHARE (Note 26) | | | | |
| Basic | <u>\$ 12.57</u> | | <u>\$ 12.34</u> | |
| Diluted | <u>\$ 12.53</u> | | <u>\$ 12.31</u> | |

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

**PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)**

| | Share Capital | | Capital Surplus | Retained Earnings | | | Other Equity | | Total Equity |
|-------------------------------------------------------------------------------------------|----------------|------------|-----------------|-------------------|-----------------|-------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|--------------|
| | Shares | Amount | | Legal Reserve | Special Reserve | Unappropriated Earnings | Exchange Differences on Translating of the Financial Statements of Foreign Operations | Unrealized Valuation Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income | |
| | (In Thousands) | | | | | | | | |
| BALANCE AT JANUARY 1, 2023 | 79,929 | \$ 799,292 | \$ 381,924 | \$ 193,575 | \$ 10,367 | \$ 1,284,172 | \$ (5,035) | \$ - | \$ 2,664,295 |
| Appropriation of 2022 earnings | | | | | | | | | |
| Legal reserve | - | - | - | 85,039 | - | (85,039) | - | - | - |
| Cash dividends distributed by the Company | - | - | - | - | - | (479,575) | - | - | (479,575) |
| Share dividends distributed by the Company | 4,796 | 47,957 | - | - | - | (47,957) | - | - | - |
| Reversal of special reserve | - | - | - | - | (5,325) | 5,325 | - | - | - |
| Changes in the Company's ownership interests in subsidiaries (Note 13) | - | - | - | - | - | (45,823) | - | - | (45,823) |
| Net profit for the year ended December 31, 2023 | - | - | - | - | - | 1,045,094 | - | - | 1,045,094 |
| Other comprehensive loss for the year ended December 31, 2023, net of income tax | - | - | - | - | - | - | (6,349) | - | (6,349) |
| Total comprehensive income (loss) for the year ended December 31, 2023 | - | - | - | - | - | 1,045,094 | (6,349) | - | 1,038,745 |
| BALANCE AT DECEMBER 31, 2023 | 84,725 | 847,249 | 381,924 | 278,614 | 5,042 | 1,676,197 | (11,384) | - | 3,177,642 |
| Appropriation of 2023 earnings | | | | | | | | | |
| Legal reserve | - | - | - | 100,009 | - | (100,009) | - | - | - |
| Special reserve | - | - | - | - | 6,342 | (6,342) | - | - | - |
| Cash dividends distributed by the Company | - | - | - | - | - | (593,074) | - | - | (593,074) |
| Changes in the Company's ownership interests in subsidiaries (Note 13) | - | - | - | - | - | (43,165) | - | - | (43,165) |
| Net profit for the year ended December 31, 2024 | - | - | - | - | - | 1,064,721 | - | - | 1,064,721 |
| Other comprehensive income (loss) for the year ended December 31, 2024, net of income tax | - | - | - | - | - | - | 18,736 | (2,847) | 15,889 |
| Total comprehensive income (loss) for the year ended December 31, 2024 | - | - | - | - | - | 1,064,721 | 18,736 | (2,847) | 1,080,610 |
| BALANCE AT DECEMBER 31, 2024 | 84,725 | \$ 847,249 | \$ 381,924 | \$ 378,623 | \$ 11,384 | \$ 1,998,328 | \$ 7,352 | \$ (2,847) | \$ 3,622,013 |

The accompanying notes are an integral part of the parent company only financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

| | 2024 | 2023 |
|-----------------------------------------------------------------------------------------|--------------------|-------------------|
| CASH FLOWS FROM OPERATING ACTIVITIES | | |
| Income before income tax | \$ 1,318,739 | \$ 1,285,756 |
| Adjustments for: | | |
| Depreciation expense | 408,802 | 348,135 |
| Amortization expense | 2,731 | 3,651 |
| Expected credit loss recognized on trade receivables | - | 4,227 |
| Net loss on fair value changes of financial assets at fair value through profit or loss | 100,222 | - |
| Finance costs | 15,697 | 10,030 |
| Interest income | (36,248) | (14,759) |
| Share of loss (profit) of subsidiaries, associates and joint ventures | 27,339 | (2,305) |
| Loss on disposal of property, plant and equipment | 5,296 | 1,373 |
| Gain on disposal of intangible assets | - | (16) |
| Write-down of inventories | 1,000 | 480 |
| Net unrealized gain on foreign currency exchange | (1,155) | - |
| Gain and relief from lease modifications | (572) | (1,015) |
| Changes in operating assets and liabilities | | |
| Trade receivables | 7,639 | 165 |
| Trade receivables from related parties | (1,560) | (4,183) |
| Other receivables | (352) | (320) |
| Inventories | (2,863) | (99,944) |
| Other current assets | (3,231) | (3,876) |
| Trade payables | (43,481) | 52,736 |
| Other payables | 12,579 | 14,872 |
| Other current liabilities | 902 | 1,949 |
| Cash generated from operations | 1,811,484 | 1,596,956 |
| Interest received | 28,701 | 14,617 |
| Interest paid | (3,307) | (618) |
| Income taxes paid | (270,031) | (210,749) |
| Net cash generated from operating activities | <u>1,566,847</u> | <u>1,400,206</u> |
| CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Purchase of financial assets at fair value through other comprehensive income | (113,521) | - |
| Purchase of financial assets at amortized cost | - | (4,733) |
| Proceeds from sale of financial assets at amortized cost | 554,363 | - |
| Purchase of financial assets at fair value through profit or loss | (1,395,595) | - |
| Acquisition of associate | - | (140,000) |
| Payments for property, plant and equipment | (424,791) | (360,299) |
| Proceeds from disposal of property, plant and equipment | 181 | 79 |
| Increase in refundable deposits | (5,319) | (62) |
| Payments for intangible assets | (2,325) | (1,253) |
| Proceeds from disposal of intangible assets | - | 70 |
| Increase in prepayments for equipment | - | (59,972) |
| Dividend received | - | 618 |
| Net cash used in investing activities | <u>(1,387,007)</u> | <u>(565,552)</u> |
| CASH FLOWS FROM FINANCING ACTIVITIES | | |
| Proceeds from short-term borrowings | 50,000 | - |
| Proceeds from guarantee deposits received | 40 | - |
| Repayments of the principal portion of lease liabilities | (146,707) | (132,871) |
| Dividends paid to owners of the Company | (593,074) | (479,575) |
| Net cash used in financing activities | <u>(689,741)</u> | <u>(612,446)</u> |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | (509,901) | 222,208 |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR | <u>603,315</u> | <u>381,107</u> |
| CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR | <u>\$ 93,414</u> | <u>\$ 603,315</u> |

The accompanying notes are an integral part of the parent company only financial statements.

Appendix 4

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
Universal Vision Biotechnology Co., Ltd.

Opinion

We have audited the accompanying consolidated financial statements of Universal Vision Biotechnology Co., Ltd. and its subsidiaries (collectively referred to as the “Group”), which comprise the consolidated balance sheets as of December 31, 2024 and 2023, and the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the “consolidated financial statements”).

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2024 and 2023, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the year ended December 31, 2024. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matter of for the Group's consolidated financial statements for the year ended December 31, 2024 is described stated as follows:

Ophthalmology Business Division - Accuracy of Technical Service Revenue

The Group's ophthalmology business division 2024 operating revenue - technical service revenue is the main revenue and is growing year by year, which has a significant impact on the consolidated financial statements; thus, we listed the accuracy of ophthalmology business division - technical service revenue as a key audit matter. For additional information on the accounting policy of revenue recognition, refer to Note 4.n. to the consolidated financial statements.

We have performed principal audit procedures for confirming the accuracy of the ophthalmology business division - technical service revenue as below:

1. We obtained an understanding of the design and tested the implementation effectiveness of internal control of the ophthalmology business division - technical service revenue.
2. We obtained the subsidiary ledger of the ophthalmology business division - technical service revenue and examined the contents, checked the contracts, relevant supporting documents and the collection of receivables to confirm the authenticity of the recognized technical service revenue.

Other Matter

We have also audited the parent company only financial statements of Universal Vision Biotechnology Co., Ltd. as of and for the years ended December 31, 2024 and 2023 on which we have issued an unmodified opinion.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended December 31, 2024 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Nai-Hua Kuo and Chung-Cheng Chen.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 6, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

| ASSETS | 2024 | | 2023 | |
|-----------------------------------------------------------------------------------------------------|---------------------|------------|---------------------|------------|
| | Amount | % | Amount | % |
| CURRENT ASSETS | | | | |
| Cash and cash equivalents (Notes 4 and 6) | \$ 506,854 | 9 | \$ 1,062,545 | 21 |
| Financial assets at fair value through profit or loss - current (Notes 4 and 7) | 1,295,373 | 22 | - | - |
| Financial assets at amortized cost - current (Notes 4, 9 and 10) | 115,216 | 2 | 578,363 | 11 |
| Trade receivables (Notes 4, 11 and 23) | 565,569 | 10 | 584,252 | 11 |
| Other receivables (Note 25) | 11,897 | - | 2,165 | - |
| Inventories (Notes 4 and 12) | 289,725 | 5 | 294,521 | 6 |
| Other current assets | 57,187 | 1 | 58,030 | 1 |
| Total current assets | 2,841,821 | 49 | 2,579,876 | 50 |
| NON-CURRENT ASSETS | | | | |
| Financial assets at fair value through other comprehensive income - non-current (Notes 4, 8 and 10) | 111,073 | 2 | - | - |
| Property, plant and equipment (Notes 4, 14 and 32) | 1,756,259 | 31 | 1,592,350 | 31 |
| Right-of-use assets (Notes 4 and 15) | 917,162 | 16 | 731,066 | 14 |
| Intangible assets (Notes 4 and 16) | 22,790 | - | 22,981 | 1 |
| Deferred tax assets (Notes 4 and 25) | 72,259 | 1 | 67,251 | 1 |
| Prepayments for equipment | - | - | 94,085 | 2 |
| Refundable deposits (Note 32) | 41,202 | 1 | 39,093 | 1 |
| Other non-current assets (Note 32) | 136 | - | 3,882 | - |
| Total non-current assets | 2,920,881 | 51 | 2,550,708 | 50 |
| TOTAL | \$ 5,762,702 | 100 | \$ 5,130,584 | 100 |
| LIABILITIES AND EQUITY | | | | |
| CURRENT LIABILITIES | | | | |
| Short-term borrowings (Notes 17 and 32) | \$ 92,012 | 2 | \$ 8,670 | - |
| Trade payables (Note 18) | 268,070 | 5 | 312,308 | 6 |
| Payables for equipment (Note 20) | 91,080 | 1 | 93,036 | 2 |
| Other payables (Note 19) | 277,453 | 5 | 260,815 | 5 |
| Current tax liabilities (Notes 4 and 25) | 154,445 | 3 | 162,567 | 3 |
| Lease liabilities - current (Notes 4 and 15) | 178,399 | 3 | 155,272 | 3 |
| Current portion of long-term borrowings (Notes 17 and 32) | - | - | 1,301 | - |
| Other current liabilities (Note 23) | 29,265 | - | 29,119 | 1 |
| Total current liabilities | 1,090,724 | 19 | 1,023,088 | 20 |
| NON-CURRENT LIABILITIES | | | | |
| Deferred tax liabilities (Notes 4 and 25) | 60,930 | 1 | 58,386 | 1 |
| Lease liabilities - non-current (Notes 4 and 15) | 783,828 | 14 | 613,018 | 12 |
| Long-term accounts payable (Note 20) | 70,908 | 1 | 92,574 | 2 |
| Guarantee deposits | 584 | - | 543 | - |
| Total non-current liabilities | 916,250 | 16 | 764,521 | 15 |
| Total liabilities | 2,006,974 | 35 | 1,787,609 | 35 |
| EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Note 22) | | | | |
| Share capital | | | | |
| Ordinary shares | 847,249 | 15 | 847,249 | 17 |
| Capital surplus | 381,924 | 7 | 381,924 | 7 |
| Retained earnings | | | | |
| Legal reserve | 378,623 | 6 | 278,614 | 5 |
| Special reserve | 11,384 | - | 5,042 | - |
| Unappropriated earnings | 1,998,328 | 35 | 1,676,197 | 33 |
| Total retained earnings | 2,388,335 | 41 | 1,959,853 | 38 |
| Other equity | 4,505 | - | (11,384) | - |
| Total equity attributable to owners of the Company | 3,622,013 | 63 | 3,177,642 | 62 |
| NON-CONTROLLING INTERESTS | | | | |
| Total equity | 133,715 | 2 | 165,333 | 3 |
| TOTAL | \$ 5,762,702 | 100 | \$ 5,130,584 | 100 |

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars, Except Earnings Per Share)

| | 2024 | | 2023 | |
|---------------------------------------------------------------------------------------------------------------|---------------------|-------------|---------------------|-------------|
| | Amount | % | Amount | % |
| OPERATING REVENUE (Notes 4 and 23) | \$ 4,228,302 | 100 | \$ 4,082,256 | 100 |
| OPERATING COSTS (Notes 12 and 24) | <u>(1,695,016)</u> | <u>(40)</u> | <u>(1,633,886)</u> | <u>(40)</u> |
| GROSS PROFIT | <u>2,533,286</u> | <u>60</u> | <u>2,448,370</u> | <u>60</u> |
| OPERATING EXPENSES (Notes 21 and 24) | | | | |
| Selling and marketing expenses | (726,754) | (17) | (704,486) | (17) |
| General and administrative expenses | (406,181) | (10) | (427,670) | (11) |
| Expected credit loss | <u>(2,444)</u> | <u>-</u> | <u>(4,363)</u> | <u>-</u> |
| Total operating expenses | <u>(1,135,379)</u> | <u>(27)</u> | <u>(1,136,519)</u> | <u>(28)</u> |
| PROFIT FROM OPERATIONS | <u>1,397,907</u> | <u>33</u> | <u>1,311,851</u> | <u>32</u> |
| NON-OPERATING INCOME AND EXPENSES | | | | |
| Interest income (Note 24) | 39,576 | 1 | 19,158 | - |
| Other income (Note 24) | 8,117 | - | 8,069 | - |
| Other gains and losses (Note 24) | (106,611) | (3) | (4,666) | - |
| Finance costs (Note 24) | <u>(20,948)</u> | <u>-</u> | <u>(15,833)</u> | <u>-</u> |
| Total non-operating income and expenses | <u>(79,866)</u> | <u>(2)</u> | <u>6,728</u> | <u>-</u> |
| PROFIT BEFORE INCOME TAX | 1,318,041 | 31 | 1,318,579 | 32 |
| INCOME TAX EXPENSE (Notes 4 and 25) | <u>(267,816)</u> | <u>(6)</u> | <u>(254,555)</u> | <u>(6)</u> |
| NET PROFIT FOR THE YEAR | <u>1,050,225</u> | <u>25</u> | <u>1,064,024</u> | <u>26</u> |
| OTHER COMPREHENSIVE INCOME (LOSS) | | | | |
| Items that may be reclassified subsequently to profit or loss: | | | | |
| Exchange differences on translation of the financial statements of foreign operations (Note 22) | 30,233 | - | (10,275) | - |
| Unrealized loss on investments in debt instruments at fair value through other comprehensive income (Note 22) | (3,559) | - | - | - |
| Income tax relating to items that may be reclassified subsequently to profit or loss (Notes 4 and 25) | <u>(3,972)</u> | <u>-</u> | <u>1,587</u> | <u>-</u> |
| Other comprehensive income (loss) for the year, net of income tax | <u>22,702</u> | <u>-</u> | <u>(8,688)</u> | <u>-</u> |
| TOTAL COMPREHENSIVE INCOME FOR THE YEAR | <u>\$ 1,072,927</u> | <u>25</u> | <u>\$ 1,055,336</u> | <u>26</u> |
| NET PROFIT ATTRIBUTABLE TO: | | | | |
| Owners of the Company | \$ 1,064,721 | 25 | \$ 1,045,094 | 26 |
| Non-controlling interests | <u>(14,496)</u> | <u>-</u> | <u>18,930</u> | <u>-</u> |
| | <u>\$ 1,050,225</u> | <u>25</u> | <u>\$ 1,064,024</u> | <u>26</u> |
| TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO: | | | | |
| Owners of the Company | \$ 1,080,610 | 25 | \$ 1,038,745 | 26 |
| Non-controlling interests | <u>(7,683)</u> | <u>-</u> | <u>16,591</u> | <u>-</u> |
| | <u>\$ 1,072,927</u> | <u>25</u> | <u>\$ 1,055,336</u> | <u>26</u> |
| EARNINGS PER SHARE (Note 26) | | | | |
| Basic | <u>\$ 12.57</u> | | <u>\$ 12.34</u> | |
| Diluted | <u>\$ 12.53</u> | | <u>\$ 12.31</u> | |

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023
(In Thousands of New Taiwan Dollars, Unless Stated Otherwise)**

| | Equity Attributable to Owners of the Company | | | | | | Other Equity | | Non-controlling Interests (Note 27) | Total Equity |
|------------------------------------------------------------------------------------|----------------------------------------------|------------|-----------------|-------------------|-----------------|----------------------------|---------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|--------------|
| | Share Capital | | Capital Surplus | Retained Earnings | | | Exchange Differences on Translating of the Financial Statements of Foreign Operations | Unrealized Valuation Gain (Loss) on Financial Assets at Fair Value Through Other Comprehensive Income | | |
| | Shares (In Thousands) | Amount | | Legal Reserve | Special Reserve | Unappropriated Earnings | | | | |
| BALANCE AT JANUARY 1, 2023 | 79,929 | \$ 799,292 | \$ 381,924 | \$ 193,575 | \$ 10,367 | \$ 1,284,172 | \$ (5,035) | \$ - | \$ 165,019 | \$ 2,829,314 |
| Appropriation of 2022 earnings | | | | | | | | | | |
| Legal reserve | - | - | - | 85,039 | - | (85,039) | - | - | - | - |
| Cash dividends distributed by the Company | - | - | - | - | - | (479,575) | - | - | - | (479,575) |
| Share dividends distributed by the Company | 4,796 | 47,957 | - | - | - | (47,957) | - | - | - | - |
| Reversal of special reserve | - | - | - | - | (5,325) | 5,325 | - | - | - | - |
| Actual acquisition of interests in subsidiaries (Note 27) | - | - | - | - | - | (45,823) | - | - | (21,277) | (67,100) |
| Non-controlling interests | - | - | - | - | - | - | - | - | 5,000 | 5,000 |
| Net profit for the year ended December 31, 2023 | - | - | - | - | - | 1,045,094 | - | - | 18,930 | 1,064,024 |
| Other comprehensive loss for the year ended December 31, 2023, net of income tax | - | - | - | - | - | - | (6,349) | - | (2,339) | (8,688) |
| Total comprehensive income (loss) for the year ended December 31, 2023 | - | - | - | - | - | 1,045,094 | (6,349) | - | 16,591 | 1,055,336 |
| BALANCE AT DECEMBER 31, 2023 | 84,725 | 847,249 | 381,924 | 278,614 | 5,042 | 1,676,197 | (11,384) | - | 165,333 | 3,342,975 |
| Appropriation of 2023 earnings | | | | | | | | | | |
| Legal reserve | - | - | - | 100,009 | - | (100,009) | - | - | - | - |
| Special reserve | - | - | - | - | 6,342 | (6,342) | - | - | - | - |
| Cash dividends distributed by the Company | - | - | - | - | - | (593,074) | - | - | - | (593,074) |
| Actual acquisition of interests in subsidiaries (Note 27) | - | - | - | - | - | (43,165) | - | - | (23,935) | (67,100) |
| Net profit for the year ended December 31, 2024 | - | - | - | - | - | 1,064,721 | - | - | (14,496) | 1,050,225 |
| Other comprehensive income for the year ended December 31, 2024, net of income tax | - | - | - | - | - | - | 18,736 | (2,847) | 6,813 | 22,702 |
| Total comprehensive income (loss) for the year ended December 31, 2024 | - | - | - | - | - | 1,064,721 | 18,736 | (2,847) | (7,683) | 1,072,927 |
| BALANCE AT DECEMBER 31, 2024 | 84,725 | \$ 847,249 | \$ 381,924 | \$ 378,623 | \$ 11,384 | \$ 1,998,328 | \$ 7,352 | \$ (2,847) | \$ 133,715 | \$ 3,755,728 |

The accompanying notes are an integral part of the consolidated financial statements.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

| | 2024 | 2023 |
|-------------------------------------------------------------------------------------------|--------------------|---------------------|
| CASH FLOWS FROM OPERATING ACTIVITIES | | |
| Income before income tax | \$ 1,318,041 | \$ 1,318,579 |
| Adjustments for: | | |
| Depreciation expense | 518,053 | 441,766 |
| Amortization expense | 3,437 | 4,380 |
| Expected credit loss recognized on trade receivables | 2,444 | 4,363 |
| Net loss on fair value changes of financial assets at fair value through profit or loss | 100,222 | - |
| Finance costs | 20,948 | 15,833 |
| Interest income | (39,576) | (19,158) |
| Loss on disposal of property, plant and equipment | 7,464 | 1,385 |
| Costs transferred from property, plant, and equipment to expenses | 1,332 | - |
| Loss (gain) on disposal of intangible assets | 1,452 | (16) |
| Write-down of inventories | 2,965 | 541 |
| Net unrealized gain on foreign currency exchange | (1,155) | - |
| Gain and relief from lease modifications | (572) | (1,719) |
| Changes in operating assets and liabilities | | |
| Trade receivables | 16,103 | (6,764) |
| Other receivables | (390) | (241) |
| Inventories | 1,800 | (89,849) |
| Other current assets | 4,595 | 11,320 |
| Trade payables | (44,238) | 57,756 |
| Other payables | 16,499 | 16,241 |
| Other current liabilities | 146 | 2,496 |
| Cash generated from operations | 1,929,570 | 1,756,913 |
| Interest received | 31,080 | 18,850 |
| Interest paid | (5,048) | (1,467) |
| Income taxes paid | (283,536) | (220,704) |
| Net cash generated from operating activities | <u>1,672,066</u> | <u>1,553,592</u> |
| CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Purchase of financial assets at fair value through other comprehensive income | (113,521) | - |
| Purchase of financial assets at amortized cost | - | (1,743) |
| Proceeds from sale of financial assets at amortized cost | 463,147 | - |
| Purchase of financial assets at fair value through profit or loss | (1,395,595) | - |
| Payments for property, plant and equipment | (434,646) | (400,861) |
| Proceeds from disposal of property, plant and equipment | 863 | 79 |
| Increase in refundable deposits | (2,808) | (947) |
| Payments for intangible assets | (2,446) | (1,748) |
| Proceeds from disposal of intangible assets | - | 70 |
| Increase in other non-current assets | - | (130) |
| Increase in prepayments for equipment | - | (71,671) |
| Decrease in prepayments for equipment | 878 | - |
| Net cash used in investing activities | <u>(1,484,128)</u> | <u>(476,951)</u> |
| CASH FLOWS FROM FINANCING ACTIVITIES | | |
| Proceeds from short-term borrowings | 82,524 | 8,848 |
| Repayments of long-term borrowings | (1,353) | (9,202) |
| Proceeds from guarantee deposits received | 40 | 8 |
| Repayments of the principal portion of lease liabilities | (184,076) | (168,633) |
| Dividends paid to owners of the Company | (593,074) | (479,575) |
| Acquisition of additional interests in subsidiaries | (67,100) | (67,100) |
| Changes in non-controlling interests | - | 5,000 |
| Net cash used in financing activities | <u>(763,039)</u> | <u>(710,654)</u> |
| EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES | <u>19,410</u> | <u>(6,461)</u> |
| NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS | <u>(555,691)</u> | <u>359,526</u> |
| CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR | <u>1,062,545</u> | <u>703,019</u> |
| CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR | <u>\$ 506,854</u> | <u>\$ 1,062,545</u> |

The accompanying notes are an integral part of the consolidated financial statements.

Appendix 5

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

2024 Statement of the Distribution of Earnings

Unit: NT\$

| Item | Amount | |
|------------------------------------------------------------------------------------------------|-----------------|-----------------|
| Beginning undistributed earnings | | \$976,772,396 |
| Plus: Net profit after tax for the period | | 1,064,720,750 |
| Less: Retained earnings adjusted due to investments accounted for using equity method (Note 1) | | (43,165,094) |
| Less: Legal reserve allocation (10%) | | (102,155,566) |
| Plus: Reversal and provision of special reserve in accordance with the law | | 11,383,526 |
| Distributable earnings for the period | | \$1,907,556,012 |
| Distributable items (Note 2) | | |
| Common share - cash dividend (NT\$7.5 per share) | (\$635,436,743) | (635,436,743) |
| Ending undistributed earnings | | \$1,272,119,269 |

Note 1: Retained earnings adjusted due to the debit balance incurred from the change in shareholding ratio (without influencing control or without significant impact).

Note 2: The undistributed earnings in 2024 were prioritized for this distribution of earnings; and the dividend amount is calculated based on the current number of shares, which is 84,724,899 shares.

Chairperson: Ou Shu-Fang

General Manager: Lu Kenneth

Accounting Manager: Sun Yu-Chiao

Appendix 6

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. Comparison Table of Articles of Incorporation Before and After Revision

| Article | After revision | Before revision | Description |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 30 | <p>The Company shall distribute 1% to 10% of the profit of the current year as employee compensation; <u>shall distribute no less than 10% of the said employee compensation to non-executive employees</u>; and shall distribute no more than 3% of the profit of the current year as director remuneration. However, if the Company still has accumulated losses, it shall make up for such losses.</p> <p>The employee compensation may be distributed in stock or cash, and the counterparty for such stock or cash may include employees of subordinate companies who meet certain conditions.</p> <p>The distribution of employee compensation (<u>including the compensation distribution ratio for non-executive employees</u>) and director remuneration shall be adopted by the Board of Directors with the attendance of two thirds or more of the directors and the consent of more than half of the directors in attendance, which shall be reported to the Shareholders Meeting.</p> | <p>The Company shall distribute 1% to 10% of the profit of the current year as employee compensation and shall distribute no more than 3% of the profit of the current year as director remuneration. However, if the Company still has accumulated losses, it shall make up for such losses.</p> <p>The employee compensation may be distributed in stock or cash, and the counterparty for such stock or cash may include employees of subordinate companies who meet certain conditions.</p> <p>The distribution of employee compensation and director remuneration shall be adopted by the Board of Directors with the attendance of two thirds or more of the directors and the consent of more than half of the directors in attendance, which shall be reported to the Shareholders Meeting.</p> | Revising the Articles of Incorporation in compliance with amendments to Paragraph 6, Article 14 of the Securities and Exchange Act, as well as FSC Order Chin-Kuan-Cheng-Fa-Tzu No. 1130385442. |
| Article 33 | <p>These Articles of Incorporation were set up on July 11, 1994.</p> <p>The 1st amendment was made on February 15, 1996.</p> <p>The 2nd amendment was made on April 30, 1996.</p> <p>The 3rd amendment was made on March 31, 1997.</p> <p>The 4th amendment was made on August 3, 1998.</p> <p>The 5th amendment was made on November 19, 1999.</p> <p>The 6th amendment was made on December 11, 2001.</p> <p>The 7th amendment was made on February 21, 2002.</p> <p>The 8th amendment was made on May 21, 2002.</p> <p>The 9th amendment was made on July 30, 2002.</p> <p>The 10th amendment was made on June 2, 2003.</p> <p>The 11th amendment was made on May 31, 2005.</p> | <p>These Articles of Incorporation were set up on July 11, 1994.</p> <p>The 1st amendment was made on February 15, 1996.</p> <p>The 2nd amendment was made on April 30, 1996.</p> <p>The 3rd amendment was made on March 31, 1997.</p> <p>The 4th amendment was made on August 3, 1998.</p> <p>The 5th amendment was made on November 19, 1999.</p> <p>The 6th amendment was made on December 11, 2001.</p> <p>The 7th amendment was made on February 21, 2002.</p> <p>The 8th amendment was made on May 21, 2002.</p> <p>The 9th amendment was made on July 30, 2002.</p> <p>The 10th amendment was made on June 2, 2003.</p> <p>The 11th amendment was made on May 31, 2005.</p> | Added amendment date. |

| Article | After revision | Before revision | Description |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| | <p>The 12th amendment was made on June 14, 2006. The 13th amendment was made on June 21, 2007. The 14th amendment was made on June 24, 2010. The 15th amendment was made on June 28, 2012. The 16th amendment was made on June 17, 2015. The 17th amendment was made on June 22, 2016. The 18th amendment was made on June 14, 2018. The 19th amendment was made on June 18, 2019. The 20th amendment was made on June 15, 2020. The 21st amendment was made on August 27, 2021. The 22nd amendment was made on June 23, 2022. <u>The 23rd amendment was made on May 26, 2025.</u></p> | <p>The 12th amendment was made on June 14, 2006. The 13th amendment was made on June 21, 2007. The 14th amendment was made on June 24, 2010. The 15th amendment was made on June 28, 2012. The 16th amendment was made on June 17, 2015. The 17th amendment was made on June 22, 2016. The 18th amendment was made on June 14, 2018. The 19th amendment was made on June 18, 2019. The 20th amendment was made on June 15, 2020. The 21st amendment was made on August 27, 2021. The 22nd amendment was made on June 23, 2022.</p> | |

Appendix 7

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Comparison Table of Procedures for Acquisition or Disposal of Assets Before and After Revision

| Article | After revision | Before Revision | Description |
|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 10 | <p>Authority for approval and decision making</p> <p>Before the Company acquires or disposes of assets specified in these Procedures, the office in charge of managing the Company's assets shall prepare all relevant assessment and necessary documents and consult with the relevant responsible departments. <u>Approval for such acquisition or disposal shall be subject to the following authority:</u></p> <p><u>1. Securities</u></p> <p>(1) <u>For the acquisition or disposal of securities traded on a centralized trading market or over-the-counter market, where the amount per transaction or per day is NT\$300 million or less, shall be submitted through an internal sign-off process to the general manager and chairperson for approval; where the amount per transaction or per day is more than NT\$300 million but no more than NT\$500 million, the chairperson may be authorized to make the decision thereon and then report it to the next board meeting for retroactive confirmation; where the amount per transaction or per day exceeds NT\$500 million, it must be approved by the Board of Directors before it can be implemented.</u></p> <p>(2) <u>For the acquisition or disposal of securities not traded on a centralized trading market or over-the-counter market, where the transaction amount is 20% or less of the paid-in capital, an investment appraisal report shall be provided with such, then the whole must be submitted</u></p> | <p>Authority for approval and decision making</p> <p>Before the Company acquires or disposes of assets specified in these Procedures, the office in charge of managing the Company's assets shall prepare all relevant assessment and necessary documents and consult with the relevant responsible departments. <u>After consultation on the acquisition or disposal proposal is completed, it shall be submitted to the general manager and chairperson for approval.</u></p> | <p>In compliance with corporate governance, revising the scope of authority for approval of and decision making on the acquisition or disposal of assets in these Procedures.</p> |

| Article | After revision | Before Revision | Description |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-------------|
| | <p><u>through internal sign-off process to the general manager and chairperson for approval; where the transaction amount exceeds 20% of the paid-in capital, it must be approved by the Board of Directors before it can be implemented.</u></p> <p><u>2. Other assets</u> <u>For the acquisition or disposal of assets other than securities, where the transaction amount is 20% or less of the paid-in capital, it shall be submitted through internal sign-off process to the general manager and chairperson for approval; where the transaction amount exceeds 20% of the paid-in capital, it must be approved by the Board of Directors before it can be implemented.</u></p> | | |

Appendix 8

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Comparison Table of Procedures for Lending Funds to Other Parties Before and After Revision

| Article | After revision | Before Revision | Description |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 1 | <p>The Company's <u>loaning of funds to others</u> shall be carried out in accordance with these Operational Procedures.</p> <p>Any matters not covered in these Procedures shall be handled in accordance with relevant laws and regulations.</p> | <p>The Company's <u>loaning of funds to other juristic persons other than shareholders (below, "borrowers" for short) for business needs</u> shall be carried out in accordance with these Operational Procedures.</p> <p>Any matters not covered in these Procedures shall be handled in accordance with relevant laws and regulations.</p> | <p>Wording appropriately revised, in accordance with the applicable scope of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies.</p> |
| Article 2 | <p>Counterparties for loaning of funds</p> <ol style="list-style-type: none"> 1. Companies or businesses that have business dealings with the Company. 2. Other companies or businesses in which the Company has re-invested. 3. Companies or businesses in need of short-term financing. "Short term" as referred to here shall refer to one year. However, where a company's operating cycle is longer than one year, such an operating cycle shall prevail. The financing amount mentioned shall refer to the accumulated balance of the Company's short-term financing funds. 4. If the Company's responsible person violates the regulations in Paragraphs 1 to 3, he/she shall be jointly and severally liable for return of the funds together with the borrower; if the Company incurs damage, he/she shall also be liable for compensation for such damage. | <p>Counterparties for loaning of funds</p> <ol style="list-style-type: none"> 1. Companies or businesses that have business dealings with the Company. 2. Other companies or businesses in which the Company has re-invested. 3. Companies or businesses in need of short-term financing. "Short term" as referred to here shall refer to one year. However, where a company's operating cycle is longer than one year, such an operating cycle shall prevail. <p>The financing amount mentioned <u>in the preceding paragraph</u> shall refer to the accumulated balance of the Company's short-term financing funds.</p> <p>If the Company's responsible person violates the <u>proviso to Paragraph 1</u>, he/she shall be jointly and severally liable for return of the funds together with the borrower; if the Company incurs damage, he/she shall also be liable for compensation for such damage.</p> | <p>Wording revised as appropriate.</p> |
| Article 4 | <p>Total amount of funds loaned and loan limits for individual counterparties</p> <ol style="list-style-type: none"> 1. (Omitted) 2. (Omitted) 3. (Omitted) | <p>Total amount of funds loaned and loan limits for individual counterparties</p> <ol style="list-style-type: none"> 1. (Omitted) 2. (Omitted) 3. (Omitted) | <p>Revisions made in accordance with Paragraph 4, Article 3 of the Regulations Governing Loaning of Funds and</p> |

| Article | After revision | Before Revision | Description |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p>4. When, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights, or when, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights and the Company itself, there is loaning of funds as required for financing, the total amount of funds loaned <u>shall not be subject to the limit of 20% of the net worth of the loaning company. However, the total amount of funds loaned and the loan limits for individual counterparties shall still be prescribed in its internal operational procedures in accordance with the provisions of the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies formulated by the competent securities authority, and the loan period shall also be clearly specified therein.</u></p> | <p>4. When, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights, there is loaning of funds as required for financing, or when, between foreign companies in which the Company directly or indirectly holds 100% of the voting rights and the Company itself, there is loaning of funds as required for financing, the total amount of funds loaned <u>shall not exceed 20% of the net worth of the loaning company, and the amount of funds loaned to an individual company shall not exceed 20% of the net worth of the loaning company. The financing period shall be limited to one year or one operating cycle.</u></p> | <p>Making of Endorsements/Guarantees by Public Companies, as well as revisions to wording as appropriate.</p> |
| Article 6 | <p>Loan period and interest calculation method</p> <p>1. The loan period for any given loan shall not in principle exceed <u>one year</u>.</p> <p>2. The interest rate for the loaning of funds shall be no lower than the highest interest rate for the Company's short-term loans taken from financial institutions. The interest on the Company's loans shall in principle be calculated and paid on a monthly basis. In the event of special circumstances, adjustments may, with approval from the Board of Directors, be made in accordance with actual circumstances.</p> | <p>Loan period and interest calculation method</p> <p>1. The loan period for any given loan shall not in principle exceed <u>180 days. In the event of special circumstances, the loan period may, with the approval of the Board of Directors, be extended in accordance with actual circumstances.</u></p> <p>2. The interest rate for the loaning of funds shall be no lower than the highest interest rate for the Company's short-term loans taken from financial institutions. The interest on the Company's loans shall in principle be calculated and paid on a monthly basis. In the event of special circumstances, adjustments may, with approval from the Board of Directors, be made in accordance with actual circumstances.</p> | <p>The loan term is set to be no more than one year in principle, in accordance with the Regulations Governing Loaning of Funds and Making of Endorsements/Guarantees by Public Companies.</p> |

Appendix 9

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Comparison Table of Rules of Procedure for Shareholders Meetings Before and After Revision

| Article | After revision | Before Revision | Description |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 3 | <p>(Convening of Shareholders Meetings and meeting notices) (1. omitted)</p> <p><u>To convene a virtual shareholders meeting, the Company must implement it via a resolution with the attendance of two thirds of the directors and the consent of more than half of the directors in attendance.</u></p> <p>The Company shall prepare the electronic version of the meeting notice, proxy forms, as well as the cause of each agenda item and description materials relating to all proposals to the Shareholders Meeting, such as acknowledgment matters, discussion matters, and the selection or dismissal of directors, and upload them to the Market Observation Post System (MOPS) 30 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting; The Company shall also prepare the electronic version of the shareholders meeting handbook and supplemental meeting materials, and upload them to the MOPS 21 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting. In addition, 15 days prior to the date of a Shareholders Meeting, the Company shall also make available the handbook and supplemental meeting materials for that Shareholders Meeting for review by shareholders at any time. The meeting handbook and supplemental meeting materials shall also be displayed at the Company and its shareholder services agent.</p> <p><u>With regard to the meeting handbook and supplemental meeting materials mentioned in the preceding paragraph, the Company shall provide them to shareholders for reference in</u></p> | <p>(Convening of Shareholders Meetings and meeting notices) (1. omitted)</p> <p>The Company shall prepare the electronic version of the meeting notice, proxy forms, as well as the cause of each agenda item and description materials relating to all proposals to the Shareholders Meeting, such as acknowledgment matters, discussion matters, and the selection or dismissal of directors, and upload them to the Market Observation Post System (MOPS) 30 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting; The Company shall also prepare the electronic version of the shareholders meeting handbook and supplemental meeting materials, and upload them to the MOPS 21 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting. In addition, 15 days prior to the date of a Shareholders Meeting, the Company shall also make available the handbook and supplemental meeting materials for that Shareholders Meeting for review by shareholders at any time. The meeting handbook and supplemental meeting materials shall also be displayed at the Company and its shareholder services agent, <u>and be distributed on-site at the venue of the Shareholders Meeting.</u></p> <p>(Omitted below)</p> | <ol style="list-style-type: none"> 1. When the Company convenes a virtual shareholders meeting, shareholders may attend without a physical meeting. to protect the rights and interests of shareholders, Paragraph 2 is thus added, requiring such meetings to be implemented via a special resolution of the Board of Directors. 2. The original Paragraph 2 is relocated to Paragraph 3. 3. The original Paragraph 3 is relocated to Paragraph 5. Also, to allow shareholders to refer to the shareholders proceedings manual and supplementary meeting materials on the day of the shareholders meeting, regardless of whether they are participating in a physical shareholders meeting or doing so via video conference, the |

| Article | After revision | Before Revision | Description |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p><u>the following manner on the day of the shareholders meeting:</u></p> <ol style="list-style-type: none"> 1. <u>When convening a physical shareholders meeting, such materials shall be distributed onsite at the shareholders meeting.</u> 2. <u>When convening a hybrid shareholders meeting, such materials shall be distributed onsite at the shareholders meeting as well as transmitted to the video conferencing platform in the form of electronic files.</u> 3. <u>When convening a virtual shareholders meeting, the electronic files shall be transmitted to the video conferencing platform.</u> <p><u>(Omitted below)</u></p> | | <p>numbering of this article is revised as appropriate, and Paragraph 4 is added.</p> <p>4. The original Paragraphs 4-9 are relocated to Paragraphs 6-11.</p> |
| Article 5 | <p>(Principles for determining the venue and time of a Shareholders Meeting) (1. omitted)</p> <p><u>When convening a virtual shareholders meeting, the Company shall not be subject to the meeting venue limitations in the preceding paragraph.</u></p> | <p>(Principles for determining the venue and time of a Shareholders Meeting) (1. omitted)</p> | <p>Paragraph 2 is added to clearly state that, when convening a virtual shareholders meeting, the Company shall not be subject to limitations on meeting venue.</p> |
| Article 6 | <p>(Preparation of documents such as the attendance book) (1. omitted)</p> <p>The time for accepting attendance registrations for shareholders shall be at least 30 minutes prior to the time the meeting commences. The place at which attendance registrations are accepted shall be clearly marked and a sufficient number of suitable personnel shall be assigned to handle the registrations. <u>For virtual shareholders meetings, the attendance registration shall be accepted on the shareholders meeting video conferencing platform at least 30 minutes prior to the time the meeting commences; shareholders that have completed the attendance registration shall be deemed to have attended the shareholders meeting in person.</u></p> <p>(3. to 6. omitted)</p> | <p>(Preparation of documents such as the attendance book) (1. omitted)</p> <p>The time for accepting attendance registrations for shareholders shall be at least 30 minutes prior to the time the meeting commences. The place at which attendance registrations are accepted shall be clearly marked and a sufficient number of suitable personnel shall be assigned to handle the registrations.</p> <p>(3. to 6. omitted)</p> | <ol style="list-style-type: none"> 1. Paragraph 2 is hereby revised to clearly prescribe times and procedures for registrations with shareholders attending virtually. 2. Paragraph 7 is hereby added, to allow shareholders attending the meeting via video conference the opportunity to read the meeting handbook, annual report, and other materials. |

| Article | After revision | Before Revision | Description |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p><u>When convening a virtual shareholders meeting, the Company shall upload the meeting handbook, annual report and other meeting materials to the virtual meeting platform at least 30 minutes before the meeting starts, and keep this information disclosed until the end of the meeting.</u></p> | | |
| Article 9 | <p>The attendance at shareholders meetings shall be calculated based on the number of shares. The number of shares in attendance shall be calculated according to the number of shares indicated on the attendance book or the sign-in card handed in <u>as well as the ones registered on the video conferencing platform</u>, plus the number of shares whose voting rights are exercised by correspondence or electronically.</p> <p>The chair shall call the meeting to order at the scheduled meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement of the meeting, provided that no more than two such postponements may be made, with the combined postponed time not exceeding one hour in total. If, after two postponements, the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned due to lack of a quorum. <u>If the shareholders meeting is held virtually, the Company shall separately declare the meeting adjourned due to lack of quorum on the virtual meeting platform.</u></p> <p>If the quorum is not met after two postponements but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Paragraph 1, Article 175 of the Company Act, and all shareholders shall be notified of the tentative resolution and another Shareholders Meeting shall be convened within one month. <u>If the shareholders meeting is held virtually, shareholders that intend to attend the meeting</u></p> | <p>The attendance at Shareholders Meetings shall be calculated based on numbers of shares. The number of shares in attendance shall be calculated according to the number of shares indicated on the attendance book or the sign-in card handed in, plus the number of shares whose voting rights are exercised by correspondence or electronically.</p> <p>The chair shall call the meeting to order at the scheduled meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement of the meeting, provided that no more than two such postponements may be made, with the combined postponed time not exceeding one hour in total. If, after two postponements, the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned due to lack of a quorum.</p> <p>If the quorum is not met after two postponements but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Paragraph 1, Article 175 of the Company Act, and all shareholders shall be notified of the tentative resolution and another Shareholders Meeting shall be convened within one month.</p> | <ol style="list-style-type: none"> 1. Paragraph 1 is hereby revised, to clearly prescribe that if a shareholders meeting is convened virtually, the number of shares represented by shareholders having completed attendance registration via video conference shall be added to the calculation of the total number of shares in attendance. 2. Paragraph 2 is hereby revised, to prescribe that if a shareholders meeting is convened virtually, then where the chair declares the meeting adjourned due to lack of a quorum, the Company shall also separately declare the meeting adjourned on the shareholders meeting video conferencing platform to inform shareholders in real time. 3. Paragraph 3 is hereby |

| Article | After revision | Before Revision | Description |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | <p><u>via video conference shall re-register their attendance with the Company in accordance with the regulations.</u></p> <p>(Omitted below)</p> | (Omitted below) | revised, to prescribe that in the event of the Company’s convening a shareholders meeting separately via a tentative resolution, shareholders that intend to attend the meeting via video conference shall register such attendance with the Company. |
| Article 11 | <p>(Speeches by shareholders) (1. to 6. omitted)</p> <p><u>When convening a virtual shareholders meeting, shareholders attending via video conference may raise questions via text on the shareholders meeting video conferencing platform, beginning once the chair declares the meeting open, and continuing until the chair declares the meeting adjourned. No more than two questions for the same proposal may be raised. Each question shall contain no more than 200 words. The provisions of Paragraphs 1 to 5 shall not apply.</u></p> | (Speeches by shareholders) (1. to 6. omitted) | Paragraph 7 is hereby added to clearly prescribe the method, procedure, and restrictions on the questions raised by shareholders attending the virtual shareholders meeting. |
| Article 19 | <p><u>When convening a virtual shareholders meeting, the Company shall, immediately after the voting is closed, disclose the voting results of all proposals and election results on the shareholders meeting video conferencing platform in accordance with regulations, and shall continue to disclose them for at least 15 minutes after the chair declares the meeting adjourned.</u></p> | These Rules shall take effect after having been submitted to and approved by the Shareholders Meeting, and subsequent revisions thereof shall be effected in the same manner. | <ol style="list-style-type: none"> 1. This article is hereby added, to allow shareholders attending the meeting via video conference the opportunity to be informed of the voting status and election results for each proposal in real time. 2. The original Article 19 is hereby relocated to Article 21. |

| Article | After revision | Before Revision | Description |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 20 | <p><u>When convening a virtual shareholders meeting where the video conferencing platform or the participation therein by video conference is disrupted continuously for 30 minutes or more due to natural disasters, accidents or other force majeure events before the chair declares the meeting adjourned, the meeting shall be postponed or resumed within five days, and Article 182 of the Company Act shall not apply.</u></p> <p><u>When convening a hybrid shareholders meeting where the meeting held via video conference cannot be continued as provided in Paragraph 1, if the total number of shares represented by the shareholders in attendance after deducting the number of shares represented by the shareholders in attendance via videoconference still meets the quorum for holding a shareholders meeting, the shareholders meeting shall still proceed, and need not be postponed or resumed in accordance with the provisions of Paragraph 1.</u></p> | (Newly added) | This article is hereby added to prescribe that, if a shareholders meeting is convened virtually; the chair has announced the meeting open; the video conferencing platform or the participation therein via video conference is then disrupted due to natural disasters, accidents or other force majeure events; and the disruption persists and cannot be eliminated for 30 minutes or more, then the meeting must be postponed or resumed on a date within five days. Article 182 of the Company Act requiring the adoption of a resolution by the shareholders meeting for this purpose shall then not apply. |
| Article 21 | <u>These Rules shall take effect after having been submitted to and approved by the Shareholders Meeting, and subsequent revisions thereof shall be effected in the same manner.</u> | (Newly added) | The original Article 19 is hereby relocated to Article 21. |

Annex 1

Articles of Incorporation of UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. (Before revision)

Chapter 1 General Provisions

- Article 1: The Company is organized in accordance with the provisions of the Company Act on companies limited by shares, and is UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.
- Article 2: The business scope of the Company is as follows:
1. F102040 Wholesale of Nonalcoholic Beverages
 2. F102170 Wholesale of Foods and Groceries
 3. F103010 Wholesale of Animal Feeds
 4. F104110 Wholesale of Cloths, Garments, Shoes, Hats, Umbrellas and Clothing Accessories
 5. F105050 Wholesale of Furniture, Bedding Kitchen Utensils and Fixtures
 6. F108021 Wholesale of Western Pharmaceutical
 7. F108031 Wholesale of Medical Devices
 8. F108040 Wholesale of Cosmetics
 9. F109070 Wholesale of Culture, Education, Musical Instruments and Educational Entertainment Supplies
 10. F110020 Wholesale of Glasses
 11. F113010 Wholesale of Machinery
 12. F113030 Wholesale of Precision Instruments
 13. F113050 Wholesale of Computers and Clerical Machinery Equipment
 14. F118010 Wholesale of Computer Software
 15. F119010 Wholesale of Electronic Materials
 16. F202010 Retail Sale of Feeds
 17. F203010 Retail Sale of Food, Grocery and Beverage
 18. F204110 Retail Sale of Cloths, Garments, Shoes, Hats, Umbrellas and Clothing Accessories
 19. F205040 Retail Sale of Furniture, Bedding Kitchen Utensils and Fixtures
 20. F208021 Retail Sale of Western Pharmaceutical
 21. F208031 Retail Sale of Medical Apparatus
 22. F208040 Retail Sale of Cosmetics
 23. F208050 Retail Over-the-counter drugs class B
 24. F209060 Retail Sale of Culture, Education, Musical Instruments and Educational Entertainment Supplies
 25. F210020 Retail Sale of Glasses
 26. F213030 Retail Sale of Computers and Clerical Machinery Equipment
 27. F213040 Retail Sale of Precision Instruments
 28. F213080 Retail Sale of Machinery and Tools
 29. F218010 Retail Sale of Computer Software
 30. F219010 Retail Sale of Electronic Materials
 31. JZ99060 Spectacles Shops
 32. I103060 Management Consulting

- 33. I301020 Data Processing Services
- 34. I301030 Electronic Information Supply Services
- 35. JZ99050 Agency Services
- 36. H703100 Real Estate Leasing
- 37. JE01010 Rental and Leasing
- 38. F401010 International Trade
- 39. JZ99080 Beauty and Hairdressing Services
- 40. JZ99110 Body Shaping Beauty Services
- 41. ZZ99999 All business activities that are not prohibited or restricted by law, except those that are subject to special approval.

Article 3: The Company has a head office in Taipei City. If necessary, after the resolution of the board meeting, the Company may set up branches in appropriate places at home and abroad in accordance with the law.

Article 4: The public announcement of the company shall be handled in accordance with Article 28 of the Company Act.

Chapter 2 Share

Article 5: The Company's authorized capital is NT\$2 billion, divided into 200 million shares, in an amount of NT\$10 per share. The Board of Directors is authorized to issue the shares in installments, of which 5 million shares are reserved for the exercise of stock options and stock warrants, which are authorized to the Board of Directors to issue in installments.

Article 5-1: If the Company intends to issue employee stock warrants at a share subscription price lower than the closing price on the issuance date, it shall submit it to the Shareholders Meeting for a resolution in accordance with the provisions of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers before the assurance may be implemented.

If the Company intends to transfer the repurchased shares of the Company to employees at a lower price than the average price of the shares actually repurchased, the Company shall submit it to the most recent Shareholders Meeting for a resolution in accordance with relevant regulations before the transfer may be implemented.

For the employee stock warrants issued by the Company, the transfer of treasury shares to employees, and the issuance of new shares, a certain proportion thereof shall be reserved to be purchased by employees in accordance with the law. In addition, the counterparty for the issuance of restricted stock award shares may include employees of subordinate companies who meet certain conditions, and the certain conditions and purchase method thereof are authorized to the Board of Directors to determine.

Article 6: The Company's share certificates shall be affixed with the signature or seal of the director representing the Company, and issued after being attested by a bank that may serve as an attester for the issuance of share certificates in accordance with the law. The Company may be exempt from printing the share certificates issued, and shall register the issued shares with the Taiwan Depository and Clearing Corporation.

Article 7: The Company's stock affairs shall be handled in accordance with the “Regulations Governing the Administration of Shareholder Services of Public Companies” promulgated by the competent authority.

Article 8: Deleted

Article 9: Deleted

Article 10: Deleted

Article 11: The registration of share transfer shall be handled in accordance with the provisions of Article 165 of the Company Act.

Chapter 3 Shareholders Meeting

Article 12: The Shareholders Meeting is divided into two types: the general meeting and special meeting. The general meeting is convened once a year, and is held within six months after the end of each fiscal year. The special meeting is convened in accordance with relevant laws and regulations when necessary, and the meeting notice shall be processed in accordance with the provisions of Article 172 of the Company Act.

When the Shareholders Meeting is in session, it may proceed by video conference or other methods announced by the central competent authority.

The meeting notice of the Shareholders Meeting, if consented by the counterparty, may be sent electronically. For shareholders holding less than 1,000 registered shares, the meeting notice referred to in the preceding paragraph may be sent by means of public announcement.

Article 13: When a shareholder is unable to attend the Shareholders Meeting for some reason, a proxy printed by the Company may be issued to specify the scope of authorization to entrust a proxy to attend the meeting. The procedures for shareholders to attend by proxy shall be in accordance with Article 177 of the Company Act as well as the “Regulations Governing the Use of Proxies for Attendance at Shareholder Meetings of Public Companies” promulgated by the competent authority.

Article 14: When the Shareholders Meeting is in session, the chairperson shall be the chair of the meeting. In the absence of the chairperson, the chairperson shall designate a director to act on his/her behalf. If no designation is made, the directors shall select one person from among themselves to act on his/her behalf.

Article 15: Unless otherwise stipulated by laws and regulations, the shareholders of the Company shall have one voting right per share.

Article 16: Unless otherwise stipulated by the Company Act, the resolution of the Shareholders Meeting shall be adopted with the attendance of shareholders representing more than half of the total number of issued shares and the consent of more than half of the voting rights of the shareholders in attendance.

Article 17: The resolutions of Shareholders Meetings shall be recorded in the meeting minutes, which shall be affixed with the signature or seal of the chair, and be distributed to all shareholders within 20 days after the

meeting.

The production and distribution of the meeting minutes in the preceding paragraph may be done electronically.

The distribution of the meeting minutes in Paragraph 1 may be done by means of public announcement.

Chapter 4 Directors and Audit Committee

- Article 18: The Company shall have five to nine directors. The election of directors shall adopt the candidate nomination system. The Shareholders Meeting shall select and appoint the directors from the list of director candidates. The term of office shall be three years, and directors may be re-elected to continue in office. The total shareholding ratio of all directors shall be subject to the regulations of the competent authority in securities.
- Article 18-1: Among the aforementioned director seats of the Company, the independent directors shall not be less than three persons, and shall not be less than one fifth of the director seats. The professional qualifications, shareholding, restrictions on part-time engagements, nomination and selection methods, and other matters to be complied with for independent directors shall be subject to the relevant regulations of the competent authority in securities.
- Article 19: When the vacancy of director seats reaches one third thereof or all independent directors are dismissed, the Board of Directors shall convene a Special Shareholders Meeting within 60 days for a by-election, and the term of office shall be limited to the remaining period of the original term.
- Article 20: When a director's term of office expires and the re-election has not been held, the performance of his/her/its duties shall be extended until the re-elected director takes office.
- Article 21: The Board of Directors shall be organized by the directors. With the attendance of two thirds of the directors and the consent of more than half of the directors in attendance, one person from among the directors shall be elected as the chairperson to represent the Company externally. For the convening of the board meeting, the reasons for the convening shall be stated in the meeting notice to be sent to all directors seven days in advance. However, in the event of an emergency, a board meeting may be convened at any time. The foregoing convening notice may be sent in writing, be fax, or electronically.
- Article 22: The Company's business policy and other important matters shall be decided by the chairperson. Except for the first board meeting for each term of the Board of Directors to be convened in accordance with the provisions of Article 203 of the Company Act, the rest board meetings shall be convened and chaired by the chairperson. When the chairperson takes leave or is unable to exercise functions and powers for some reason, the representation shall be handled in accordance with the provisions of Article 208 of the Company Act.
- Article 23: The resolutions of the Board of Directors, unless otherwise provided by the Company Act, shall be adopted with the attendance of more than

half of the directors and the consent of more than half of the directors in attendance. If a director is unable to attend the meeting for some reason, a power of attorney may be issued specifying the scope of authorization for the meeting agenda, to entrust another director to attend the board meeting on his/her/its behalf, provided that a director may accept the appointment to act as the proxy of one director only.

Article 24: The proceedings of board meetings shall be recorded in meeting minutes, which shall be affixed with the signature or seal of the chair, and be distributed to all directors within 20 days after the meeting. The meeting minutes shall record the main points and results of the proceedings. The meeting minutes shall be safekept in the Company together with the signature book for the attending directors and the proxy for the attendance by proxy.

Article 25: The Company shall set up an Audit Committee to replace the functions and powers of superiors. The Audit Committee shall be composed of all independent directors, with no less than three members, one of whom shall be the convener. The exercise of its functions and powers as well as related matters shall be handled in accordance with relevant laws and regulations.

The Board of Directors of the Company may set up various functional committees. The qualifications of their members, the exercise of functions and powers, and other related matters shall be handled in accordance with relevant laws and regulations, and shall be separately determined by the Board of Directors.

Article 25-1: The Board of Directors is authorized to determine the director remuneration according to the level of each director's participation in the operation of the Company and the value of the contribution, and taking account of the domestic standards of the same trade.

Article 25-2: The Company may purchase directors and important employees liability insurance for directors and important employees upon the resolution of the Board of Directors.

Chapter 5 Managers and Staff

Article 26: The Company may have managers, whose appointment, dismissal, and remuneration shall be handled in accordance with Article 29 of the Company Act.

Article 27: The Company may engage consultants and important employees by the resolution of the Board of Directors.

Article 28: Deleted.

Chapter 6 Final Accounts

Article 29: At the end of the fiscal year, the Board of Directors shall prepare the following books and statements to be submitted to the General Shareholders Meeting for acknowledgment.

1. Business report
2. Financial statements
3. Proposal for earnings distribution or loss appropriation

Article 30: The Company shall distribute 1% to 10% of the profit of the current year as employee compensation and shall distribute no more than 3% of the profit of the current year as director remuneration. However, if the Company still has accumulated losses, it shall make up for such losses.

The employee compensation may be distributed in stock or cash, and the counterparty for such stock or cash may include employees of subordinate companies who meet certain conditions.

The distribution of employee compensation and director remuneration shall be adopted by the Board of Directors with the attendance of two thirds or more of the directors and the consent of more than half of the directors in attendance, which shall be reported to the Shareholders Meeting.

Article 30-1: If the Company has a surplus in the annual final accounts, it shall first set aside the amount for tax payments, make up for the losses of previous years, and then set aside 10% of the balance as the legal reserve; however, when the legal reserve has reached the paid-in capital, the foregoing 10% provision may be exempted; and the special reserve shall be set aside or reversed in accordance with the law. If there is still a surplus in the current year, in combination with the accumulated undistributed earnings in the previous years, the Board of Directors shall draw up a proposal for distribution of earnings to be submitted to the Shareholders Meeting for a resolution.

When the Company sets aside the special reserve according to the law, for the insufficient amount for the “net increase in fair value of investment property accumulated in the prior period” and “net decrease in other equity accumulated in the prior period”, the same amount of special reserve shall be set aside from the undistributed earnings in the previous period prior to the distribution of earnings. If it is still insufficient, items other than the current net profit after tax shall be added to the current net profit after tax to be included in the amount of the current undistributed earnings for the provision.

If the Company intends to distribute dividends and bonuses or all or part of the legal reserve and capital reserve in cash, the Board of Directors is authorized to determine with the attendance of two thirds or more of the directors, and the consent of more than half of the directors in attendance, which shall be reported to the Shareholders Meeting.

The Company shall appropriately adopt the distribution of stock dividends or cash dividends, taking into account the environment and growth stage that the Company is in and goes through, in response to future capital needs and long-term financial planning, and also considering the maintenance of stable dividend distribution, and the distribution amount shall not be less than 30% of the distributable earnings for the year, of which the cash dividends shall not be less than 30% of the total dividends.

Chapter 7 Supplementary Provisions

Article 31: The organizational rules and work rules of the Company shall be separately formulated by the Board of Directors.

Article 31-1: The Company may undertake external guarantees for business or investment needs.

Article 31-2: For the business needs of this company, the total amount of all investments may not be required to be subject to the restriction on not exceeding 40% of the Company's paid-in share capital under the Company Act.

Article 32: Any matter not provided for in these articles of incorporation shall be handled in accordance with the Company Act and other laws.

Article 33: These Articles of Incorporation were set up on July 11, 1994.

The 1st amendment was made on February 15, 1996.

The 2nd amendment was made on April 30, 1996.

The 3rd amendment was made on March 31, 1997.

The 4th amendment was made on August 3, 1998.

The 5th amendment was made on November 19, 1999.

The 6th amendment was made on December 11, 2001.

The 7th amendment was made on February 21, 2002.

The 8th amendment was made on May 21, 2002.

The 9th amendment was made on July 30, 2002.

The 10th amendment was made on June 2, 2003.

The 11th amendment was made on May 31, 2005.

The 12th amendment was made on June 14, 2006.

The 13th amendment was made on June 21, 2007.

The 14th amendment was made on June 24, 2010.

The 15th amendment was made on June 28, 2012.

The 16th amendment was made on June 17, 2015.

The 17th amendment was made on June 22, 2016.

The 18th amendment was made on June 14, 2018.

The 19th amendment was made on June 18, 2019.

The 20th amendment was made on June 15, 2020.

The 21st amendment was made on August 27, 2021.

The 22nd amendment was made on June 23, 2022.

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Chairperson: OU, SHU-FANG

Annex 2

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. Rules of Procedure for Shareholders Meetings (Before revision)

- Article 1: In order to establish a strong governance system, perfect supervisory capabilities, and enhance management functions for the Company's Shareholders Meetings, these Rules are formulated pursuant to Article 5 of the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies.
- Article 2: The rules of procedures for the Company's Shareholders Meetings, except as otherwise provided by laws, regulations, or the Articles of Incorporation, shall be as provided in these Rules.
- Article 3: (Convening of Shareholders Meetings and meeting notices)
Unless otherwise provided by laws or regulation, the Company's Shareholders Meetings shall be convened by the Board of Directors.
The Company shall prepare the electronic version of the meeting notice, proxy forms, as well as the cause of each agenda item and description materials relating to all proposals to the Shareholders Meeting, such as acknowledgment matters, discussion matters, and the selection or dismissal of directors, and upload them to the Market Observation Post System (MOPS) 30 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting; The Company shall also prepare the electronic version of the shareholders meeting handbook and supplemental meeting materials, and upload them to the MOPS 21 days prior to the date of a General Shareholders Meeting or 15 days prior to the date of a Special Shareholders Meeting. In addition, 15 days prior to the date of a Shareholders Meeting, the Company shall also make available the handbook and supplemental meeting materials for that Shareholders Meeting for review by shareholders at any time. The meeting handbook and supplemental meeting materials shall also be displayed at the Company and its shareholder services agent, and be distributed on-site at the venue of the Shareholders Meeting.
The reasons for convening a Shareholders Meeting shall be specified in the meeting notice and public announcement; with the consent of the counterparty, the meeting notice may be sent in electronic form.
The selection or dismissal of directors, amendments to the Articles of Incorporation, reduction of capital, application for delisting, exemption from non-compete restrictions for directors, earnings converted to capital increase, reserves converted to capital increase, dissolution, merger, or demerger of the Company, or any matter set forth in various subparagraphs of Paragraph 1, Article 185 of the Company Act, Articles 26-1 and 43-6 of the Securities Exchange Act, as well as Articles 56-1 and 60-2 of the Regulations Governing the Offering and Issuance of Securities by Securities Issuers shall be set out and the essential contents explained in the meeting agenda of the Shareholders Meeting. None of the above matters may be raised by an extraordinary motion.
Where the re-election of all directors as well as the date of taking office are clearly stated in the meeting agenda of the Shareholders Meeting, after the completion of the re-election in the said Shareholders Meeting, the date of taking office may not be changed by any extraordinary motion or other means at the same meeting.
A shareholder holding one percent or more of the total number of issued shares may submit to the Company a proposal for discussion at a General Shareholders Meeting. The number of proposals that may be put forward is limited to one only, otherwise all such proposals shall not be included in the meeting agenda. In addition, where any one of the circumstances in any subparagraph of Paragraph 4, Article 172-1 of the Company Act applies to a proposal put forward by a shareholder, the Board of Directors may exclude it from the agenda. A shareholder may propose a recommendation for urging the Company to promote public interests or fulfill its social responsibilities, provided that procedurally the number of proposals so put forward shall be limited to only one in accordance with Article 172-1 of the

Company Act, otherwise all such proposals shall not be included in the meeting agenda.

The Company shall publicly announce the shareholder proposal accepted, the method accepted by correspondence or electronically, as well as the location and time period for accepting the proposal prior to the book closure date and before the date of the General Shareholders Meeting; and the period for accepting the shareholder proposal may not be less than 10 days.

The proposals put forward by shareholders are limited to 300 words only, and no proposal containing more than 300 words will be included in the meeting agenda. The shareholder put forward the proposal shall attend in person or by proxy the General Shareholders Meeting and take part in the discussion regarding the said proposal.

The Company shall inform the shareholder who put forward the proposal of the proposal pre-screening results prior to the date of the meeting notice of a Shareholders Meeting, and shall include in the meeting notice the proposals that conform to the provisions of this article. At the Shareholders Meeting, the Board of Directors shall explain the reasons for exclusion of any shareholder proposals not included in the agenda.

Article 4: For each Shareholders Meeting, a shareholder may appoint a proxy to attend the meeting by providing the proxy printed by the Company and stating clearly the scope of authorization. A shareholder may issue only one proxy, and appoint only one proxy for any Shareholders Meeting, and shall deliver the proxy to the Company five days prior to the date of the Shareholders Meeting. When duplicate proxies are delivered, the one received earliest shall prevail unless a statement is made to cancel the previous proxy. After a proxy has been delivered to the Company, if the shareholder intends to attend the meeting in person or intends to exercise voting rights by correspondence or electronically, a written notice of revoking the proxy shall be submitted to the Company two days prior to the meeting date; If the notice of revocation is submitted after the deadline, the vote cast at the meeting by the proxy shall prevail.

Article 5: (Principles for determining the venue and time of a Shareholders Meeting)
The venue for a shareholders meeting shall be the premises of the Company or a place conveniently accessible to shareholders and suitable for a shareholders meeting. The meeting may begin no earlier than 9 a.m. or no later than 3 p.m. Full consideration shall be given to the opinions of independent directors with respect to the venue and time of the meeting.

Article 6: (Preparation of documents such as the attendance book)
The Company shall specify in its shareholders meeting notices the time and location for accepting attendance registrations for shareholders, as well as other matters to be paid attention to.

The time for accepting attendance registrations for shareholders shall be at least 30 minutes prior to the time the meeting commences. The place at which attendance registrations are accepted shall be clearly marked and a sufficient number of suitable personnel shall be assigned to handle the registrations.

The shareholder him/her/itself or the proxy appointed by the shareholder (hereinafter referred to as the shareholder) shall attend Shareholders Meetings based on attendance cards, sign-in cards, or other certificates of attendance. Solicitors soliciting proxies shall also bring their identification documents for verification.

The Company shall furnish the attending shareholders with an attendance book to sign, or attending shareholders may hand in a sign-in card in lieu of signing in.

The Company shall furnish attending shareholders with the meeting handbook, annual report, attendance card, speaker's slips, voting slips, and other meeting materials. Where the election of directors is in the agenda, pre-printed ballots shall also be furnished.

When the government or a juristic person is a shareholder, it may be represented by more than one representative at a Shareholders Meeting. When a juristic person is appointed to attend as proxy, it may designate only one representative to attend the meeting.

Article 7: (The chair and participants in a Shareholders Meeting)
If a Shareholders Meeting is convened by the Board of Directors, the meeting shall be chaired by the chairperson. When the chairperson is on leave or for any reason unable to exercise the functions and powers, the vice chairperson shall act on behalf of the chairperson; where there

is no vice chairperson or the vice chairperson is also on leave or for any reason unable to exercise the functions and powers, the chairperson shall appoint one of the managing directors to act on his/her behalf; where there are no managing directors, one of the directors shall be appointed to act on his/her behalf; and where the chairperson does not make any designation, the managing directors or the directors shall select from among themselves one person to act on his/her behalf.

If a shareholders meeting is convened by a person with the convening right but other than the Board of Directors, the said person with the convening right shall chair the meeting. When there are two or more such persons with the convening right, they shall select a chair from among themselves. The Company may appoint the attorney, certified public accountant, or related persons retained by it to participate in a Shareholders Meeting.

Article 8: (Documentation of a shareholders meeting by audio or video)

The Company shall make an audio and video recording of the entire proceedings of the Shareholders Meeting, which shall be retained for at least one year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the recording shall be retained until the conclusion of the litigation.

Article 9: The attendance at Shareholders Meetings shall be calculated based on numbers of shares. The number of shares in attendance shall be calculated according to the number of shares indicated on the attendance book or the sign-in card handed in, plus the number of shares whose voting rights are exercised by correspondence or electronically.

The chair shall call the meeting to order at the scheduled meeting time. However, when the attending shareholders do not represent a majority of the total number of issued shares, the chair may announce a postponement of the meeting, provided that no more than two such postponements may be made, with the combined postponed time not exceeding one hour in total. If, after two postponements, the attending shareholders still represent less than one third of the total number of issued shares, the chair shall declare the meeting adjourned due to lack of a quorum.

If the quorum is not met after two postponements but the attending shareholders represent one third or more of the total number of issued shares, a tentative resolution may be adopted pursuant to Paragraph 1, Article 175 of the Company Act, and all shareholders shall be notified of the tentative resolution and another Shareholders Meeting shall be convened within one month.

When, prior to conclusion of the meeting, the attending shareholders have represented a majority of the total number of issued shares, the chair may resubmit the tentative resolution for a vote by the Shareholders Meeting pursuant to Article 174 of the Company Act.

Article 10: (Discussion of proposals)

If a Shareholders Meeting is convened by the Board of Directors, the meeting agenda shall be determined by the Board of Directors. Votes shall be cast on each separate proposal in all the relevant agenda (including extraordinary motions and revisions of the original proposals set out in the agenda). The meeting shall proceed in the order set by the agenda, which may not be altered without a resolution of the Shareholders Meeting.

The provisions of the preceding paragraph shall apply *mutatis mutandis* to a Shareholders Meeting convened by a person with the convening right other than the Board of Directors.

The chair may not declare the meeting adjourned prior to completion of deliberation on the meeting agenda scheduled in the preceding two paragraphs (including extraordinary motions), except by a resolution of the Shareholders Meeting; If the chair declares the meeting adjourned in violation of the rules of procedure, the other board members shall promptly assist the attending shareholders in electing a new chair in accordance with statutory procedures, with the consent of a majority of the votes represented by the attending shareholders, in order to continue the meeting.

The chair shall allow ample opportunity during the meeting for explanation and discussion of proposals and revisions or extraordinary motions put forward by the shareholders; when the chair is of the opinion that a proposal has been discussed sufficiently to put it to a vote, the chair may announce the discussion closed, call for a vote, and schedule sufficient time for voting.

Article 11: (Speeches by shareholders)

Before making speeches, an attending shareholder must specify on a speaker's slip the subject of the speech, his/her shareholder account number (or attendance card number), and account name. The order in which shareholders speak shall be set by the chair.

A shareholder in attendance who has submitted a speaker's slip but does not actually speak shall be deemed to have not made the speech. When the content of the speech does not correspond to the subject given on the speaker's slip, the spoken content shall prevail.

Except with the consent of the chair, a shareholder may not speak more than twice on the same proposal, and a single speech may not exceed 5 minutes. If the shareholder's speech violates the rules or exceeds the scope of the agenda item, the chair may terminate the speech.

When an attending shareholder is speaking, other shareholders may not speak or interrupt unless they have sought and obtained the consent of the chair and the shareholder that has the floor; the chair shall stop any violation.

When a juristic person shareholder appoints two or more representatives to attend a Shareholders Meeting, only one of the representatives so appointed may speak on the same proposal.

After an attending shareholder has made the speech, the chair may respond in person or direct relevant personnel to respond.

Article 12: (Calculation of voting shares and recusal system)

The voting at a Shareholders Meeting shall be calculated based the number of shares.

With respect to resolutions of Shareholders Meetings, the number of shares held by a shareholder with no voting rights shall not be counted as part of the total number of issued shares.

When a shareholder is an interested party in relation to an agenda item, which is likely to prejudice the interests of the Company, that shareholder may not vote on that item, and may not exercise voting rights as proxy for any other shareholder.

The number of shares for which voting rights may not be exercised in the preceding paragraph shall not be counted as part of the voting rights represented by attending shareholders.

With the exception of a trust enterprise or a shareholder services agent approved by the competent authority in securities, when one person is concurrently appointed as proxy by two or more shareholders, the voting rights represented by that proxy may not exceed three percent of the voting rights represented by the total number of issued shares. The voting rights in excess of that percentage shall not be included in the calculation.

Article 13: A shareholder shall be entitled to one vote for each share held, except when the shares are restricted shares or are non-voting shares under Paragraph 2, Article 179 of the Company Act.

When the Company holds a Shareholder Meeting, it shall adopt the exercise of voting rights by electronic means and may adopt the exercise of voting rights by correspondence; When voting rights are exercised by correspondence or electronic means, the method of exercise shall be specified in the shareholders meeting notice. A shareholder exercising voting rights by correspondence or electronic means shall be deemed to have attended the meeting in person, but to have waived his/her rights with respect to the extraordinary motions and the revision of original proposals at that meeting.

A shareholder intending to exercise voting rights by correspondence or electronic means in the preceding paragraph shall deliver the expression of intent to the Company two days prior to the date of the Shareholders Meeting. When duplicate expressions of intent are delivered, the one received earliest shall prevail, except when a statement is made to revoke the earlier expression of intent.

After a shareholder has exercised voting rights by correspondence or electronic means, in the event the shareholder intends to attend the Shareholders Meeting in person, a written expression of intent to revoke the voting rights already exercised in the preceding paragraph shall be made known to the Company by the same means by which the voting rights had been exercised two days prior to the date of the Shareholders Meeting; If the notice of revocation is submitted after the deadline, the voting rights already exercised by correspondence or electronic means shall prevail. When a shareholder has exercised voting rights both by

correspondence or electronic means and by appointing a proxy to attend a Shareholders Meeting, the voting rights exercised by the proxy at the meeting shall prevail.

Except as otherwise provided by the Company Act and the Company's Articles of Incorporation, the passage of a proposal shall require an affirmative vote of a majority of the voting rights represented by the attending shareholders. At the time of the voting, for each proposal, the chair or a person designated by the chair shall first announce the total number of voting rights represented by the attending shareholders, followed by a poll of the shareholders. After the conclusion of the meeting and on the same day when it is held, the results for each proposal as to the number of affirmative votes, negative votes, and abstained votes shall be entered into the MOPS.

When there is a revision of or an alternative to a proposal, the chair shall combine such revisions or alternatives with the original proposal and decide the order in which they will be put to a vote. When any one among them is passed, the other proposals shall be deemed rejected, and no further voting shall be required.

Vote monitoring and counting personnel for the voting on a proposal shall be appointed by the chair, provided that all monitoring personnel shall be shareholders of the Company.

Vote counting for shareholders meeting proposals or elections shall be conducted in public within the venue of the Shareholders Meeting. Immediately after vote counting has been completed, the results of the voting, including the numbers of votes tallied, shall be announced on-site at the meeting, and a record shall be made of the voting result.

Article 14: (Election matters)

The election of directors at a Shareholders Meeting shall be held in accordance with the relevant rules formulated by the Company, and the voting result shall be announced on-site immediately, including the names of the directors elect as well as the number of votes they received.

The ballots for the election in the preceding paragraph shall be safekept properly for at least one year. If, however, a shareholder files a lawsuit pursuant to Article 189 of the Company Act, the ballots shall be retained until the conclusion of the litigation.

Article 15: Matters relating to resolutions of Shareholders Meetings shall be recorded in the meeting minutes, which shall be affixed with the signature or seal of the chair of the meeting, and a copy of which shall be distributed to each shareholder within 20 days after the conclusion of the meeting. The meeting minutes may be produced and distributed in electronic form.

The Company may distribute the meeting minutes in the preceding paragraph by means of a public announcement made through entries on the MOPS.

The meeting minutes shall accurately record the year, month, day, venue, the chair's name, the resolution method, a summary of the deliberations, and the voting result of the meeting (including the number of voting rights tallied), and disclose the number of voting rights won by each candidate in the case of an election of directors. The minutes shall be retained for the duration of the existence of the Company.

Article 16: (Public disclosure)

On the day of a Shareholders Meeting, the Company shall compile in the prescribed format a statistical statement of the number of shares obtained by solicitors through solicitation as well as the number of shares represented by proxies, and shall make an express disclosure of the same within the venue of the Shareholders Meeting.

If resolution matters at a Shareholders Meeting involves material information under applicable laws or regulations or regulations issued by the Taipei Exchange, the Company shall upload the content of such resolution to the MOPS within the prescribed time limit.

Article 17: (Maintaining order at the meeting place)

The staff handling administrative affairs of a Shareholders Meeting shall wear identification cards or arm bands.

The chair may direct the pickets or security personnel to assist in maintaining order at the meeting place. When pickets or security personnel maintain order at the meeting place, they shall wear an identification card or arm band bearing the wording of "Picket".

Where the meeting place is equipped with amplifying equipment in which a shareholder attempts to make a speech through any device other than the public address equipment set up

by the Company, the chair may prevent the shareholder from so speaking.

When a shareholder violates the rules of procedure and defies the chair's correction, thereby obstructing the proceedings of the meeting and refusing to follow the instruction to stop, the chair may direct the picket or security personnel to escort the shareholder out of the meeting place.

Article 18: (Recess and resumption of the meeting)

When a meeting is in progress, the chair may announce a recess as appropriate. If a force majeure event occurs, the chair may rule the meeting temporarily suspended and announce a time when, in view of the circumstances, the meeting will be resumed.

In the event that the venue is no longer available for continued use for the meeting and the agenda items (including extraordinary motions) scheduled have yet to be concluded, the Shareholders Meeting may adopt a resolution to resume the meeting at another venue sought otherwise.

A resolution may be adopted at a Shareholders Meeting to defer or continue the meeting within five days in accordance with Article 182 of the Company Act.

Article 19: These Rules shall take effect after having been submitted to and approved by the Shareholders Meeting, and subsequent revisions thereof shall be effected in the same manner.

Annex 3

UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.

Shareholding Status of All Directors

1. The Company's paid-in capital is in the amount of NT\$847,248,990, and the total number of issued shares is 84,724,899 shares.
2. According to Article 2 of the “Rules and Review Procedures for Director and Supervisor Share Ownership Ratios in Public Companies”, the minimum number of shares held by all directors is 6,777,991 shares.
3. The Company has set up an Audit Committee, and thus there is no application of the number of shares required to be held by supervisors under the law.
4. The shareholding status of individual and all directors recorded in the shareholder register as of the book closure date (March 28, 2025) for this Shareholders Meeting is set out in the following table:

| Title | Name | Shareholding | Ratio of shareholding |
|-----------------------------------------|-------------------------------------------------------------------------|--------------|-----------------------|
| Chairperson | Representative of Quny Development Enterprise Co., Ltd.: Ou Shu-Fang | 7,515,138 | 8.87% |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Lin Pi-Jung | 7,515,138 | 8.87% |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Weng Su-Hei | 7,515,138 | 8.87% |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Chou Tsan-Der | 7,515,138 | 8.87% |
| Director | Representative of Quny Development Enterprise Co., Ltd.: Chang Hong-Jen | 7,515,138 | 8.87% |
| Independent Director | Xiao Min-Zhi | 0 | 0.00% |
| Independent Director | Liu Vincent | 0 | 0.00% |
| Independent Director | Yang Yun-Hua | 0 | 0.00% |
| Independent Director | Chen Wei-Ju | 0 | 0.00% |
| Total shareholding of the all directors | | 7,515,138 | 8.87% |